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Abstract
Bayesian adaptive clinical trial designs are slowly gaining momentum in practice due
to their accuracy, flexibility and efficiency in evaluating a novel drug. In this thesis,
we propose novel Bayesian adaptive designs for early phase oncology trials. First, we
discuss a Phase I-II trial design for therapeutic cancer vaccines and propose a two-
stage approach for identifying the optimal vaccination schedule from multiple candidate
vaccination schedules. We model binary outcomes for toxicity and immune response and
a continuous outcome for the magnitude of immune response, conditional on a non-zero
immune response. Our results suggest that incorporating more sources of information in
a two-stage approach provides adequate power to identify the optimal schedule by trial
completion. Next, we propose a novel Bayesian adaptive Phase I trial design that uses
hierarchical modeling to share information across multiple patient populations, which
may have different background standards-of-care. We propose hierarchical extensions
for three models commonly used in Phase I clinical trials and propose three novel dose-
finding guidelines that allow us to take full advantage of hierarchical modeling while
protecting patient safety. We conclude by extending our hierarchical modeling approach
to Phase I-II dose-escalation studies, where dose selection is based on both toxicity and
efficacy. Our simulation results show that hierarchical modeling increases the probability
of correctly identifying the maximum tolerated dose or optimal dose without increasing
the rate of dose limiting toxicities. The results in this thesis are promising and motivate
further research to investigate the practical challenges in implementing our proposed
designs.
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Chapter 1
Introduction
The clinical development of a novel drug is a long and expensive process. The new
drug first goes through years of laboratory testing and sometimes animal testing before
reaching clinical evaluation in humans. These pre-clinical studies investigate the drug’s
half-life, basic pharmacokinetics (i.e., what the body does to the drug) and pharmaco-
dynamics (i.e., what the drug does to the body). The new drug then proceeds through
three phases of clinical investigation before approval. The “early” and “middle” phase
(Phase I and Phase II in the U.S., respectively) treat relatively small numbers of pa-
tients to evaluate safety and establish an optimal dose for further investigation in a
large confirmatory trial (Phase III). Once approved, Phase IV post-market surveillance
trials are often completed. These studies observe dynamic populations for side-effects
related to the newly approved treatment.
In 2006, the United States Food and Drug Administration (FDA) released a Criti-
cal Path Opportunities List outlining 76 initial projects to guide investigators in an
attempt to improve the drug development process. This document highlighted the need
for innovative trial designs, especially those incorporating prior knowledge or accumu-
lated information in the design. Subsequently, an increasing number of adaptive clinical
trial designs have been proposed and implemented due to their ability to flexibly and
efficiently evaluate novel treatments (Chow et al., 2008). In February 2010, the FDA
circulated a non-specific draft guidance on adaptive clinical trials, which was generally
supportive of properly employed adaptive designs (Food and Drug Administration et al.,
1
22010).
Broadly speaking, an adaptive clinical trial design refers to a design that allows modifi-
cations to the trial and/or statistical procedure while the trial is ongoing (Chow et al.,
2005). The Pharmaceutical Research Manufacturers Association Working Group on
Adaptive Designs makes a further distinction, stating that any design that allows mod-
ifications based on accumulating data is considered adaptive (Gallo et al., 2006). Chow
et al. (2008) and Chow and Corey (2011) discuss the advantages and limitations of
commonly used adaptive clinical trial designs. Adaptive designs can be either outcome
or covariate (patient characteristics) dependent. Adaptive designs have been proposed
that alter a number of trial characteristics based on accumulating data, including but
not limited to dosage, sample size and randomization allocation. These designs allow
investigators to efficiently evaluate several characteristics of a novel treatment in a single
trial. This dissertation will investigate novel Bayesian adaptive methods for early phase
cancer clinical trials.
1.1 Phase I Clinical Trials
The primary objective of a Phase I clinical trial is to evaluate the safety profile of a novel
treatment and identify the maximum tolerated dose (MTD), defined as the highest dose
with an acceptable toxicity rate less than some pre-defined target toxicity level (TTL,
typically 0.3 in Phase I cancer trials). The primary endpoint in Phase I clinical trials
is typically a binary indicator of whether or not the patient experienced a dose-limiting
toxicity (DLT). A DLT is an adverse event, or toxic side-effect, that is severe enough to
prevent increasing the dosage. In Phase I oncology trials, investigators define adverse
events and classify their severity using the Common Terminology Criteria for Adverse
Events (CTCAE). Typically, a subset of the Grade 3 and 4 toxicities outlined in the
CTCAE are used to define a DLT. A second objective of Phase I clinical trials is to
identify the appropriate dose for future study in Phase II clinical trials. Historically, re-
searchers assumed both the probability of toxicity and the probability of tumor response
increased monotonically with dose and the MTD was considered the dose most likely
to result in tumor response. However, this monotonicity assumption may not be valid
3for newer biologically targeted treatments, which motivates designs that consider both
toxicity and efficacy during dose-finding. Finally, due to the severe toxicity of novel
cancer treatments, Phase I cancer trials enroll patients for whom standard treatments
have failed. As a result, there is a desire to treat as many patients as possible at doses
close to the MTD to maximize the number of patients receiving a biologically active
dose, which creates additional challenges for Phase I clinical trials in oncology.
Phase I clinical trials take the form of dose-escalation studies, where initial patients
are treated at the lowest dose-level and subsequent patients are treated at progres-
sively higher dose-levels until the MTD is identified. Phase I dose-escalation studies can
broadly be classified as rule-based or model-based. Rule-based designs are simple and
easy to implement. Dose escalation or de-escalation is based on the presence or absence
of a DLT in the previous cohort. The most commonly used rule-based design is the 3+3
design (see e.g. Storer (1989)). The traditional 3 + 3 design escalates in cohorts of three
subjects until the MTD is identified. In the 3 + 3, the MTD is defined as the highest
dose with at least six patients treated and no more than one patient experiencing a
DLT. Other examples of rule-based designs include the biased coin design (Stylianou
and Flournoy, 2002), which escalates with probability TTL1−TTL , where TTL is the target
DLT rate, if the previous cohort did not experience toxicity and always de-escalates if
the previous cohort experienced a toxicity, and the broad class of up-and-down designs
proposed to improve upon the 3 + 3 and biased-coin design (Ivanova et al., 2003). Cur-
rently, the 3 + 3 design is the most commonly used dose-finding design in the United
States (Riviere et al., 2015) even though several authors have shown that the 3 + 3 will
reach the MTD slowly, treat a small number of patients at the MTD, and is likely to
produce an MTD that is futile when studied in Phase II trials (Garrett-Mayer, 2006;
Goodman et al., 1995; Iasonos et al., 2008; O’Quigley and Shen, 1996; Jaki et al., 2013;
Braun, 2014).
Alternatively, dose-escalation studies can be model-based, where dose-finding is guided
by a formal statistical model for the dose-toxicity relationship. Unlike the 3+3 design,
escalation or de-escalation in a model-based design is based on all available data, rather
than only considering the outcomes for the previous cohort. The continual reassessment
4method (CRM) (O’Quigley et al., 1990) is the most commonly used model-based design.
The basic CRM uses a simple parametric model for the dose-toxicity relationship and is
typically implemented under the Bayesian statistical paradigm. The dose-finding algo-
rithm updates the dose-toxicity curve after each cohort, with the next cohort treated at
the current estimate of the MTD based on all available data. Additional modifications
to the CRM, such as starting at the lowest dose level and not allowing dose-levels to
be skipped during escalation, have been proposed to ensure patient safety (Goodman
et al., 1995; Korn et al., 1994). Numerous extensions to the CRM have been proposed to
improve estimation and accommodate the challenges faced by clinical researchers (Babb
et al., 1998; Cheung and Chappell, 2000; Legedza and Ibrahim, 2001; Neuenschwander
et al., 2008; Yin and Yuan, 2009; Liu et al., 2015; O’Quigley and Paoletti, 2003; Braun
and Wang, 2010; Iasonos and O’Quigley, 2012, 2013).
1.2 Phase II Clinical Trials
Once a new treatment has been shown to be safe in Phase I, the next step in the drug
development process is to evaluate its potential efficacy in a Phase II clinical trial. Phase
II is an important step in the drug development process that is often sub-divided into
Phase IIA and Phase IIB. Phase IIA trials typically consist of single-arm trials where
measures of treatment efficacy are compared to historical benchmarks of performance,
while Phase IIB trials are typically small randomized trials to compare the new treat-
ment to the standard-of-care or other experimental treatments. In oncology trials, the
primary endpoint for Phase IIA trials is typically a binary measure of tumor response
(i.e., did the tumor shrink or not), while Phase IIB trials often consider survival end-
points like time-to-disease progression.
The most commonly used Phase IIA design in oncology is Simon’s two-stage design
(Simon, 1989). Simon’s two-stage design is a one-arm trial that compares the response
rate of the new drug to historical standards. In Stage 1, initial subjects are enrolled and
the trial terminates for futility if there is substantial evidence against the alternative
hypothesis. Otherwise, the trial continues to Stage 2 where the observed response rate
is compared to the historical response rate for the standard-of-care, assumed to be fixed
5and known. Simon (1989) discusses both optimal and minimax two-stage designs, which
minimize the expected or maximum sample size, respectively. Alternately, continuous
monitoring can be implemented in one-arm Phase IIA designs using Bayesian predic-
tive probabilities (Lee and Liu, 2008). Continuous monitoring can reduce the expected
sample size compared to a simpler two-stage design, but comes at the cost of additional
complexity. In general, adaptation in the context of Phase IIA trials focuses primar-
ily on sequential testing, and involves a trade-off between the additional complexity of
more frequent monitoring and the benefits of reducing the time and number of patients
needed to achieve a significant result.
Phase IIB trials are randomized trials comparing the new treatment to the standard-of-
care or other experimental treatments. Standard approaches to randomized, multi-arm
clinical trials are well-understood and readily accepted. The challenge to completing
these trials in oncology is a result of the need to rigorously evaluate the new treatments
with limited resources (typically, only 40 - 200 patients are treated in Phase IIB trials),
combined with the desire to provide patients with access to the best treatment available
for their condition. This motivates investigators to consider more complex, adaptive
approaches to maximize resources. The earliest adaptive design for Phase IIB trials is
the “play-the-winner” rule (Zelen, 1969). Under the this rule, the next patient will be
treated with the same treatment as the current patient if the current patient responds,
but will be treated with the alternate treatment if the current patient does not respond.
Adaptive randomization, which alters the randomization ratio based on accumulating
data from the trial, has been proposed as an approach to maximize the number of pa-
tients receiving the optimal treatment in a clinical trial (Thall and Wathen, 2007; Berry
et al., 2010). The utility of adaptive randomization is currently a topic of debate in the
literature (Korn and Freidlin, 2011; Lee et al., 2012; Thall et al., 2015).
1.3 Phase I-II Designs
Historically, Phases I and II have been treated as two distinct stages in the development
of a new cancer treatment. In Phase I, the MTD is identified under the assumption that
the probabilities of DLT and tumor response increase monotonically with dose and, as
6a result, the MTD is the dose most likely to achieve an efficacious response with accept-
able toxicity. Then, in Phase IIA, the efficacy of the MTD is evaluated to determine if
the new treatment should advance in the development process. An alternate approach,
referred to as Phase I-II designs, is to evaluate both safety and efficacy in a single trial
that considers the trade-off between efficacy and toxicity during dose-finding. These
designs are appealing because they can detect a situation where the drug’s efficacy
may plateau or diminish after a certain dose level but toxicity continues to increase, in
which case further escalation is undesirable, or where the MTD has unacceptable effi-
cacy, in which case the treatment is unlikely to achieve a successful outcome in Phase II.
There are two major components to a Phase I-II trial design: the joint probability model
for efficacy and toxicity, and the metric for evaluating the trade-off between efficacy and
toxicity. Several authors have used copula models to specify the joint probability of effi-
cacy and toxicity (Thall and Cook, 2004; Braun, 2002), while a non-parametric approach
(Yin et al., 2006) has also been considered. However, these models incorporate complex
correlation structures for efficacy and toxicity that may be difficult to estimate and,
in some cases, simulation results have illustrated that a simple model that ignores the
correlation between efficacy and toxicity may be adequate (Cunanan and Koopmeiners,
2014). In addition, several approaches have been proposed for evaluating the trade-off
between efficacy and toxicity, including: efficacy/toxicity trade-off contours (Thall and
Cook, 2004), a weighted Euclidean distance from target probabilities of efficacy and
toxicity (Braun, 2002) and efficacy-toxicity odds ratios (Yin et al., 2006). Alternatively,
many authors have proposed combining the two outcomes into one outcome (Thall and
Russell, 1998; Zhang et al., 2006), to evaluate the trade-off between efficacy and toxicity
without drastically increasing the parameter space. Once the model and trade-off met-
ric are specified, these designs proceed similarly to the CRM, with each cohort treated
at the current estimate of the optimal dose based on the data from all previous cohorts.
Numerous authors have expanded on the basic idea of a Phase I-II design that considers
both efficacy and toxicity for a number of specialized scenarios (Thall and Russell, 1998;
Braun, 2002; Zohar and Chevret, 2007; Thall and Cook, 2004; Zhang et al., 2006; Yin
et al., 2006; Zhong et al., 2012; Koopmeiners and Modiano, 2014).
71.4 Dissertation Objectives
In this dissertation, we propose novel Bayesian adaptive trial designs for early phase
cancer clinical trials. Phase I-II designs have been developed primarily in the context
of dose-escalation studies. However, there are some clinical applications where dose-
escalation is not of primary interest, such as therapeutic cancer vaccines. In Chapter
2, we discuss a Bayesian adaptive Phase I-II clinical trial design for a novel autologous
vaccine for high grade meningiomas. In this application, investigators are interested
in comparing different vaccination schedules, rather than different dose-levels. We de-
velop a two-stage design using binary toxicity and immune response outcomes and a
continuous outcome for the magnitude of immune response to determine the optimal
vaccination schedule. If a conclusive result cannot be reached after the first stage,
Bayesian predictive probabilities are used to determine the sample size needed in Stage
2 to achieve a conclusive result.
In Chapter 3, we investigate hierarchical modeling in the context of Phase I dose-
escalation studies. Researchers are often interested in evaluating the safety of a new
drug in multiple patient populations with different background standards-of-care. In this
case, researchers typically complete independent Phase I trials in the different popula-
tions, which may or may not result in different estimates of the MTD across populations.
This is an expensive and time-consuming process that ignores the fact that information
regarding the MTD in one population can also be found in the outcomes of patients
in other populations. We consider a novel trial design that uses hierarchical modeling
to share information across populations studied in multiple, parallel Phase I clinical
trials. We propose hierarchical extensions of three commonly used dose-response mod-
els for Phase I trial designs, and propose dose-finding guidelines that allow us to take
full advantage of hierarchical modeling while protecting patient safety. Our simulation
results indicate hierarchical modeling increases the probability of correctly identifying
the MTD and the average number of patients treated at the MTD, without increasing
the rate of DLTs.
In Chapter 4, we extend this work to evaluate the use of hierarchical modeling in Phase
8I-II dose-finding trials that consider efficacy in addition to toxicity. We propose hierar-
chical extensions of three commonly used dose-response models for multiple outcomes.
Similar to Chapter 3, our results suggest hierarchical modeling increases the probability
of correctly identifying the optimal dose and the average number of patients treated at
the optimal dose for each population, with a minimal increase in the toxicity rate for
some cases. Finally, in Chapter 5 we summarize our findings and discuss directions for
future research in this clinically important area.
Chapter 2
A Bayesian Adaptive Phase I-II
Trial Design for Therapeutic
Cancer Vaccines
2.1 Introduction
The traditional approach to Phase I clinical trials in cancer (i.e. dose-escalation studies
to identify the MTD) was developed primarily to evaluate the safety of new chemother-
apeutic agents. Recently, the field of cancer therapeutics has expanded to include other
approaches to cancer treatment including therapeutic cancer vaccines, which boost the
immune system’s ability to treat an existing cancer by using weakened or killed cancer
cells in conjunction with a specific cancer-associated antigen or modified immune cells
that express such an antigen (National Cancer Institute, 2006). Therapeutic cancer
vaccines can either be autologous or allogenic, depending on the origin of the cancer
cells. Autologous vaccines use cancer cells from the individual patient, while allogenic
vaccines use cells from another patient (National Cancer Institute, 2006). A large num-
ber of cancer-associated antigens have been identified. Furthermore, researchers often
add adjuvants to further stimulate the immune system. Hence, a vast number of poten-
tially efficacious vaccine therapies, from various combinations of antigens and adjuvants,
require investigation. Ideally, we want to identify the combination that yields not only
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the largest response rate and magnitude, but minimizes the rate of toxic side effects.
Researchers at the University of Minnesota are interested in completing a Phase I-II
clinical trial of a novel autologous vaccine for high grade meningiomas, an aggressive
form of brain tumor. Toxicity will be measured by the frequency of dose limiting toxic-
ities (DLTs), while efficacy will be evaluated by the presence and magnitude of immune
response. In this case, our efficacy outcome is a combination of a binary indicator for
the presence of immune response and, conditional on observing a response, a continuous
measure of the magnitude of response. The researchers are not interested in completing
a dose-escalation study. In fact, they are not interested in comparing multiple dose
levels at all, but are rather interested in comparing two different vaccination schedules,
which will deliver the same dose level with differing frequencies. In the first vaccina-
tion scheme, patients receive the regimen daily for 4 days every 4 weeks for the first
12 weeks, then once every 4 weeks until disease progression or 1 year. In the second
schedule, vaccination is once every week for the first 12 weeks, then once every 4 weeks
until disease progression or 1 year.
The literature investigating dose-schedule optimization in the context of Phase I dose-
escalation studies is limited (Thall et al., 2013; Braun et al., 2005; Zhang and Braun,
2013). In most cases, these designs assume the competing dose-schedules are nested
(Braun et al., 2005; Zhang and Braun, 2013), which implies a natural ordering of the
schedules. In contrast, the schedules in our motivating example are not nested and have
no natural ordering. Recently Thall et al. (2013) investigated simultaneous optimization
of dose and schedule with non-nested schedules in the context of a Phase I-II clinical
trial. Their design evaluated efficacy by considering the time-to-tumor response. In
contrast, we propose to evaluate the efficacy of therapeutic cancer vaccines using the
presence and magnitude of immune response. Furthermore, we will take advantage of
the lack of an ordering for our vaccination schedules by randomizing patients to each
vaccination schedule, rather than using a deterministic dose- or schedule-finding algo-
rithm for assigning patients to a schedule. Numerous randomized, multistage Phase II
designs that evaluate several experimental treatments have been proposed (Strauss and
Simon, 1995; Yao and Venkatraman, 1998; Yao et al., 1996; Thall et al., 1989), but these
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designs assume Phase II objectives and thus require large sample sizes after the toxicity
profile has already been established in previous trials.
We propose a two-stage randomized trial design for selecting the best vaccination sched-
ule from several candidate schedules, incorporating objectives from both Phase I and
Phase II trials. In the case of two candidate vaccination schedules, we first randomize
patients to one of the two schedules in Stage 1. At the end of Stage 1, we compare
the rate of DLTs and immune response for each schedule to pre-specified minimum
performance standards. Schedules that meet the minimum performance standard are
then compared to each other using the magnitude of immune response, to identify the
better schedule. If the superiority of a single schedule cannot be established after the
first stage, Bayesian predictive probabilities are used to determine the additional sample
size required to identify the better vaccination schedule in the second stage.
The remainder of this chapter proceeds as follows. In Section 2.2, we describe proba-
bility models for DLTs, the presence and magnitude of immune response and propose a
two-stage design for the simple case of comparing two vaccination schedules. In Section
2.3, we present simulation results evaluating the operating characteristics of our pro-
posed design and discuss its overall performance. In Section 2.4, we describe extending
our design to K schedules and present initial simulation results evaluating its perfor-
mance. Section 2.5 concludes this manuscript with a brief discussion of the benefits and
practicality of our proposed design.
2.2 Probability Model and Trial Design
2.2.1 Probability Model and Prior Specification
We begin by introducing notation and presenting a joint probability model for toxicity
and immune response. For now, we suppress the subscripts i, which indicates patient,
and k, which indicates vaccination schedule, to simplify notation. Let X be a binary
indicator of whether the subject experienced DLT, which follows a Bernoulli distribu-
tion with probability piT . Immune response has two components: a binary indicator of
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whether the subject had an immune response, and a continuous measure of the magni-
tude of response for subjects experiencing an immune response. Let Y be a Bernoulli
random variable with probability piE that takes the value 1 if a subject had an immune
response and 0 otherwise, and let Z be the continuous measure of the magnitude of
response, which follows a conditional distribution with Z|Y = 1 ∼ logNormal(µ, σ2)
and f(Z|Y = 0) = 0 with probability 1. Note that the conditional probability density
function f(Z|Y = 0) has a point mass at zero so the marginal distribution of Z is not
absolutely continuous. It was recently shown that the correlation between efficacy and
toxicity could not be estimated reliably given the limited sample sizes found in Phase
I-II clinical trials but also that failing to model this correlation had little impact on the
operating characteristics of the trial (Cunanan and Koopmeiners, 2014). We therefore
assume independence between DLTs and immune response to avoid unnecessarily in-
creasing the complexity of our model.
Suppose that n patients are randomized to each vaccination schedule and we observe
the following 3-tuples for each patient, where the full dataset for schedule k is dk =
{(xk,1, yk,1, zk,1), (xk,2, yk,2, z2), . . . , (xk,n, yk,n, zk,n)}. Then the joint likelihood for im-
mune response and toxicity is:
L(piT, piE, µ, σ
2|d) ∝
K∏
k=1
n∏
i=1
pi
xk,i
T,k (1−piT,k)1−xk,i
(
piE,k × f(zk,i|µk, σ2k)
)yk,i (1−piE,k)1−yk,i ,
where f(·) is a log Normal density function.
We must specify a prior distribution for all parameters to complete our Bayesian anal-
ysis. We specify Beta(1, 1) priors for both the toxicity and immune response rates,
piT and piE , respectively. This prior specification is identical to a Uniform(0, 1); it
has a conjugate distributional form and is thus computationally preferred. We set
µ ∼ Normal(0, τ2 = 3) for the average magnitude of non-zero immune responses (on
the log scale). Lastly, we use a Uniform(0, b = 2) prior on σ, specifying an upper
bound. This is the Jeffrey’s prior for σ with known µ. We originally considered the
conjugate inverse gamma prior for σ2, but its performance was poor. We will complete
a sensitivity analysis, varying τ2 and b, to evaluate the sensitivity of the results found
in Section 2.3 to the priors for µ and σ.
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The joint posterior distribution, p(piE , µ, σ
2|d), is not available in closed form. Instead,
we approximate the posterior distribution by sampling from the posteriors p(piE |d) and
p(µ, σ2|d) using the Gibbs sampler. In zero-inflated models, a “data augmentation”
step is incorporated into the Gibbs sampler to approximate the posterior distributions
(Ghosh et al., 2006). Summaries of the posterior (i.e., posterior mean, median, etc.)
are calculated by summarizing the Gibbs draws from the posterior.
2.2.2 Therapeutic Cancer Vaccine Trial Design
We now present a randomized, two-stage study design for evaluating the safety and
immune response of therapeutic cancer vaccines. Our basic approach is to randomize
patients between the two vaccination schedules, determine if the probabilities of a DLT
and immune-response satisfy a minimum level of clinical performance, then if necessary,
select the schedule with the largest average magnitude of immune response (defined as
a function of the immune response rate, as well). If Stage 1 does not give a conclusive
result, we continue to Stage 2 and use predictive probabilities to determine the sample
size required for Stage 2. We first consider the simple case of two vaccination schedules,
as in our motivating example, and discuss generalizing to K schedules in Section 2.4.
In Stage 1, we randomize n1 patients to each vaccination schedule and determine which,
if any, of the schedules achieves a minimum performance level in response rates. Let piT
be the pre-specified maximum acceptable DLT rate and piE be the pre-specified mini-
mum acceptable immune response rate. We define a schedule, k to be acceptable if the
posterior probabilities of the two events piT,k < piT and piE,k > piE exceed pre-specified
thresholds γT and γE , respectively, i.e.,
Pr(piT,k < piT |dk) > γT
and Pr(piE, > piE |dk) > γE , (2.1)
similar to the admissibility criteria of Thall and Russell (1998) and Thall and Cook
(2004). However, we use more stringent response requirements for the associated pos-
terior distributions. In traditional dose-finding studies, investigators understand the
practical need to treat patients below and above the MTD, especially early in the trial.
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A primary objective in designing a Phase I dose finding algorithm is to maximize the
number of patients treated at the true MTD. Traditionally, γE and γT are low (between
0.05 and 0.20, Berry et al. (2010)) since we are making a decision with often only 3,
6, or 9 patients, early in the trial. We use similar criteria to Thall and Russell (1998)
and Thall and Cook (2004), but require a smaller type 1 error, so to speak, in making
a decision after stage 1 using 10 or 15 patients, given the larger sample size compared
to dose-finding cohorts.
After Stage 1, there are four possible outcomes, as follows. If both schedules do not
satisfy Criteria (2.1) with n1 patients treated in each schedule arm, we stop the trial and
declare both vaccination schedules to be clinically unacceptable. If only one schedule is
acceptable, we stop the trial and declare the acceptable schedule to be the better sched-
ule. Alternately, if both satisfy Criteria (2.1), we compare the magnitudes of immune
response and potentially expand the trial as described below.
Define θk to be the expected magnitude of immune response for schedule k, E(Zk),
i.e.,
θk = P (Zk > 0|k)E (Zk|Zk > 0, k)
= piE,kexp
(
µk +
1
2
σ2k
)
= exp
(
µk +
1
2
σ2k + logpiE,k
)
. (2.2)
We can calculate θk for each iteration of the Gibbs sampler, and use these samples to
approximate the posterior for θk. To determine superiority when both schedules are
acceptable, we compare the two posterior expected magnitudes of immune response.
A priori we assume equal variances for the two schedules, i.e., σ2k = σ
2 for k = 1, 2,
which allows cancellation of σ2 when considering the ratio of the two schedules’ expected
magnitudes of immune response, θ2/θ1. This is reasonable since Phase I-II clinical trial
sample sizes are limited and consequently sparse.
We use the posterior probability that θ2 > θ1 to determine whether a schedule has
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a superior expected magnitude of immune response. If Pr (θ2 > θ1|d) > 1− γθ, we de-
clare Schedule 2 to be the better schedule. If Pr (θ2 > θ1|d) < γθ, we declare Schedule 1
to be better. This is equivalent to comparing the (1− 2γθ)% Bayesian credible interval
(CI) to 1 and declaring superiority if the CI is either completely above or completely
below 1. If superiority cannot be achieved, we use posterior predictive probabilities to
calculate the additional sample size required to achieve a definitive result.
Posterior predictive probabilities (PP ) provide the probability of observing a conclusive
result after Stage 2, conditional on the data observed in stage 1 and the stage-two sample
size for each schedule, n2. Our goal is to identify 2 ∗ n2 such that the predictive proba-
bility of reaching a conclusive result exceeds β. We define some notation to simplify our
expression for PP . Let Ak = I{Pr(piT,k < piT |dk) > γT } × I{Pr(piE,k > piE |dk) > γE}
for k = 1, 2. For each n2 = 1, 2, 3, . . . , n−n1, we can calculate the predictive probabilities
as
PP = Ed∗({A1 = 1 ∩ [A2 = 0 ∪ Pr[θ2 > θ1|d,d∗] < γθ)} (2.3)
∪ {A2 = 1 ∩ [A1 = 0 ∪ Pr[θ2 > θ1|d,d∗] > 1− γθ)})
=
∑
d∗
Pr(d∗|d)× (A1 × I{A2 = 0 ∪ Pr[θ2 > θ1|d,d∗] < γθ)}
+A2 × I{A1 = 0 ∪ Pr[θ2 > θ1|d,d∗] > 1− γθ)}),
where d∗ is the unobserved set of Stage 2 patients’ outcomes. Note we can generate d∗
using the assumed models for (X,Y, Z) and sample (piT , piE , µ, σ
2) from the joint pos-
terior distributions. We compute (2.3) for n2 = 1, 2, . . . until PP ≥ β or n2 = n − n1,
where n is a pre-specified maximum sample size for each schedule (Berry et al., 2010).
If the predictive probability exceeds β for some n2 = 1, 2, . . . , n − n1, we randomize
n2 subjects to each schedule and compare the schedules’ mean magnitudes of immune
response, as described above.
In summary, our proposed design proceeds as follows:
• Stage 1:
1. Randomize 2 ∗ n1 patients in a 1:1 ratio to the two vaccination schedules
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2. Evaluate Pr(piT < piT |d) > γT and Pr(piE > piE |d) > γE for both schedules
to determine if they meet the minimum performance standard. There are
four possible outcomes:
– Neither schedule is acceptable: terminate the study and declare both
schedules ineffective.
– Schedule 1 is acceptable and Schedule 2 is not: terminate the study and
declare Schedule 1 the better schedule.
– Schedule 2 is acceptable and Schedule 1 is not: terminate the study and
declare Schedule 2 the better schedule.
– Both schedules are acceptable: compare the schedules by the magnitude
of immune response.
3. Compare the magnitude of immune response by considering Pr (θ2 > θ1|d).
There are three possible outcomes:
– Pr (θ2 > θ1|d) > 1− γθ: declare Schedule 2 the better schedule.
– Pr (θ2 > θ1|d) < γθ: declare Schedule 1 the better schedule.
– γθ < Pr (θ2 > θ1|d) < (1− γθ): determine the sample size required to
achieve a conclusive result using predictive probabilities.
4. Calculate the sample size required to achieve a conclusive result in Stage 2,
2 ∗ n2, using (2.3): There are two possible outcomes:
– n2 > n − n1, where n is a pre-specified maximum sample size for each
schedule: terminate the study and declare an equivocal result.
– n2 ≤ n− n1: continue to Stage 2.
• Stage 2:
1. Randomize 2 ∗ n2 patients in a 1:1 ratio to the two vaccination schedules.
2. Compare the two schedules and identify the better schedule following steps
2 and 3 in Stage 1. After Stage 2, the possible outcome are:
– Schedule 1 is the better schedule.
– Schedule 2 is the better schedule.
– Both schedules are acceptable but we cannot identify an better schedule.
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2.3 Simulation Study
We conducted a simulation study to evaluate the operating characteristics of our pro-
posed design. Following our motivating example, we consider two vaccination schedules,
which we will refer to as Schedules 1 and 2. Recall that in our design, we define a vac-
cination schedule as minimally clinically viable for both toxicity and immune response
if Criteria (2.1) is satisfied. For this simulation, we require at least a 50% immune
response rate, piE = 0.5, and no more than a 25% toxicity rate, piT = 0.25. These
are typical immune response and toxicity rates in oncology trials. This means a sched-
ule being acceptable if piT < 0.25 and piE > 0.5, and a schedule is unacceptable if
piT ≥ 0.25 or piE ≤ 0.5. To determine the operating characteristics of our design, we
consider the following scenarios: both schedules are unacceptable because the toxicity
rate, immune response rate, or both are unacceptable; one schedule is acceptable and
the other schedule is not; and finally, both schedules are acceptable but one schedule is
better because it has a higher response rate or magnitude of immune response.
A number of design parameters must be specified to implement our design: n1, n,
γT , γE , γθ and β. These design parameters can be tuned via simulation to the achieve
the desired operating characteristics of the study. We completed numerous small simula-
tions to identify the optimal combination of design parameters for our example and have
chosen the following combination of design parameters: n1 = 10, n = 50, γT = 0.70,
γE = 0.50, γθ = 0.10 and β = 0.60. Simulation results assuming these design parame-
ters are shown in the next section. Additional simulation results evaluating the impact
of varying these design parameters will be discussed and are presented in the Supple-
mentary Materials in Table 2.5.
All simulations were completed in R version 3.1.1 and Gibbs sampling was completed
in JAGS 3.1.0 as called from R using rjags (Plummer, 2011). 1000 simulated trials were
completed for each scenario. Within each trial, 5000 iterations were kept for inference
following a period of 5000 iterations for burn-in. If a trial is found inconclusive after
stage 1, we simulate 100 Stage 2 sub-trials to calculate the predictive probability and
additional 2 ∗ n2 required to determine superiority.
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2.3.1 Results
Table 2.1 presents results for our null scenarios. In the first case, we assume both
schedules have an unacceptable toxicity rate of 25% and immune response rate of 50%,
i.e. (piT = 0.25, piE = 0.5). Next, we consider the case where both schedules have
acceptable immune response rates but are unsafe, i.e., (0.25, 0.9). Finally, we consider
the case where both are safe but have unacceptable immune response rates, i.e., (0.05,
0.5). We will primarily evaluate our design by considering the probability of reaching
each of the various conclusions after Stages 1 and 2. After Stage 1, the four conclusions
are: neither schedule is acceptable (none), Schedule 1 is better (Schedule 1), Schedule
2 is better (Schedule 2) and both are acceptable but we are unable to identify a better
schedule (Inconcl.). The same conclusions can be reached after Stage 2. In addition, we
also present the probability that the trial was inconclusive but did not continue onto
stage 2 because the sample size required to achieve the desired predictive probability
exceeded our pre-specified maximum (Stop Trial). The probabilities of reaching the
various conclusions after each stage sum to 1. In addition, we also present the ex-
pected overall sample size, EN = 2 × (n1 + Pr(continuing onto Stage 2) × n¯2), where
n¯2 is the average sample size per schedule in stage 2 conditional on expanding to stage 2.
From Table 2.1, we see that our design has acceptable performance in correctly iden-
tifying both schedules as unacceptable after stage 1. For (piT = 0.25, piE = 0.5), 79%
of all simulated trials correctly identify both schedules as unsafe and futile, while 20%
of all simulated trials incorrectly select either Schedule 1 or Schedule 2. The expected
overall sample size is 20.2 patients, suggesting that our design is unlikely to continue to
stage 2. When both schedules have high immune response rates, i.e., piE = 0.9, but are
unsafe, i.e., piT = 0.25, our design correctly concludes that neither schedule is acceptable
in 61% of all simulated trials. Alternatively, when both schedules are safe but futile,
i.e., (piT = 0.05, piE = 0.5), our design correctly identifies neither schedule as acceptable
in 38% of all simulated trials. This is due to our choosing a lower critical threshold
value for declaring efficacy because efficacy will be further evaluated in future trials
and the loss associated with declaring an ineffective schedule acceptable is less than the
loss associated with declaring an unsafe schedule acceptable. We could decrease the
probability of selecting an unacceptable schedule in this scenario by increasing γE .
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Table 2.2 presents operating characteristics for our alternative scenarios. The results are
broken down into two strata. In the first stratum, Schedule 1 is unacceptable (piT = 0.25,
piE = 0.5), while Schedule 2 is acceptable with piT = 0.1 and various combinations of
piE = {0.65, 0.8, 0.95} and µ2 = {0, log(2)}. In the second stratum, both schedules have
a toxicity rate of 0.1 and immune response rate of 0.95 (i.e., nearly perfect toxicity and
immune response rates) but we vary µ2 while leaving µ1 = 0 to determine the ability of
our model to distinguish between schedules that differ only in the magnitude of immune
response. In the first stratum of Table 2.2 when only Schedule 2 is acceptable, we cor-
rectly identify Schedule 2 as better in 51-67% of all simulated trials after Stage 1, with
only a 2.6-3.5% increase after Stage 2. We are unable to reach a conclusive result after
stage 1 in 4.3-6.1% of trials and expand to Stage 2 in 3.6-5.3% of all simulated trials.
This results in a total expected sample size less than 22 in all cases, suggesting that our
design has adequate power for correctly identifying the better schedule with the small
sample sizes typically observed in Phase I cancer trials.
We observe a larger benefit from our two-stage approach in the second stratum. In
the second stratum, both schedules have the same toxicity and immune response rate
(0.1, 0.95) but we vary the magnitude of immune response for Schedule 2 from µ2 = 0 to
µ2 = log(3). The probability of correctly identifying the better schedule increases from
47.3%, with µ2 = log(1.5), to 69.9% of the time, when µ2 = log(3). More importantly,
the second stratum illustrates the advantage of our two-stage approach. For example,
when µ2 = log(1.5), we decrease the chance of equivocal results from 38.1% after stage
1 to 22.5% after Stage 2 and increase the chance of correctly identifying the better
schedule from 32.9% after Stage 1 to 47.3% after Stage 2, while only increasing the
total sample size by 9.8 patients, on average. Similarly, when µ2 = log(2), we decrease
the chance of equivocal results from 26.8% after Stage 1 to 11.0% after Stage 2 and
increase the chance of correctly identifying the better schedule from 47.8% after Stage
1 to 63.1% after Stage 2, while only increasing the total sample size by 3.2 patients, on
average. An increase in power was also observed for µ2 = log(3) but the difference was
not as dramatic, as the rate of equivocal results after Stage 1 was much lower than the
other two cases.
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We completed additional simulations to evaluate the impact of varying the design pa-
rameters specified above on the operating characteristics of our trial. First, we per-
formed additional simulation studies for an increased Stage 1 sample size but keeping
the same maximum sample size, n = 50 per schedule. We considered n1 = 15 with
maximum n2 = 35 and n1 = 20 with maximum n2 = 30 per schedule. Increasing n1
increased the probability of correctly identifying the better schedule, but came at the
cost of substantially increasing the average total sample size. Specifically, we observed
a 10-15% increase in the probability of correctly identifying the better schedule, but
a 20-30% increase in the total sample size when n1 = 15, and a 25-50% increase in
the total sample size when n1 = 20. Furthermore, we observe that increasing n1 to 20
negates the benefits of the two-stage design because trials that are inconclusive after
Stage 1 will likely require a much larger sample size to achieve a conclusive result. From
these results, we see that n1 = 15 provides a reasonable trade-off between the power
and sample size and would be a reasonable choice; but the trade-off between power and
sample size for n1 = 20 was less desirable. We ran smaller simulation studies to see how
sensitive our operating characteristics were to changes in γT , γE , γθ and β, changing
one parameter at a time. The results can be found in the Supplementary Materials
at the end of the chapter. Most notably, increasing β or decreasing γθ resulted in a
decreased probability of correctly selecting the better schedule at study completion and
an increase in the number of trials that stop after Stage 1 with an inconclusive result.
For a prior sensitivity analysis (also presented in Section 2.6, Supplementary Mate-
rials), we varied the upper limit for our Uniform(0, b) prior on σ from b = 1, 2, 5, 10
and we varied the variance for our Normal(0, τ2) prior on µ from τ2 = 1, 3, 10, 100,
assuming the same simulation and design parameters discussed in Section 2.3. These
changes had very little impact on the operating characteristics of our two-stage design.
2.4 Extending to K Vaccine Therapies
To this point, we have only considered the case of two vaccination schedules for simplic-
ity. However, we can easily extend our design to K schedules as follows. In Stage 1, we
randomize n1 patients to each of the K schedules. After Stage 1, estimate piT,k and piE,k
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for each schedule, k, and determine if any of the K schedules meet the minimum clinical
performance levels. After identifying the clinically acceptable schedules, we compare the
posterior expected magnitudes of immune response to identify the superior schedule. If
a conclusive result cannot be determined in the first stage, we take the top two schedules
to Stage 2 and calculate the additional sample size required using Bayesian predictive
probabilities, as described in Section 2.2.2. We can implement hierarchical modeling to
share response information across schedules and potentially improve estimation (Berry
et al., 2010). Instead of fixing the prior mean magnitude of response, µk ∼ N(0, 3) for
k = 1, . . .K, we allow the average mean magnitude response to be estimated using all
K responses, i.e.
µk ∼ N(β, τ2)
β ∼ N(0, 3); τ2 ∼ IG(3, 1),
where IG is an inverse gamma distribution. Note the variance parameter, τ2, controls
the amount of sharing across schedules for estimating the mean magnitude of response.
Our prior specification for τ2 suggests little to no sharing across schedules, a priori.
We now briefly investigate the performance of our design in the extended case through
a small simulation study. We consider four scenarios with K = 4 schedules per sce-
nario. In the first scenario, only one schedule meets the minimum performance level,
Criteria (2.1); the toxicity and response rates for the four vaccination schedules are
{(0.1, 0.8), (0.25, 0.5), (0.05, 0.5), (0.35, 0.8)}, respectively, with µk = 0 for all k = 1 : 4.
In the second and third scenarios, there are two acceptable schedules, Schedules 1 and 2,
with toxicity and immune response rates equal to (0.1, 0.95) and (0.1, 0.65), respectively,
but we set µ1 = 0 in Scenario 2 and µ1 = log(1.5) in scenario 3. Finally, in Scenario
4, Schedules 1 and 2 have the same toxicity and immune response rates, (0.1, 0.95), but
µ1 = log(2), compared to µ2 = 0. The true toxicity rate, immune response rate and
magnitude of immune response for Schedules 3 and 4 remain the same throughout the
four scenarios considered.
Results from 1000 simulated trials for Scenarios 1-4 are displayed in Figure 2.1. The
white fill represents the probability of reaching each conclusion after Stage 1, the dark
fill represents the increase in the probability of reaching each conclusion when the trial
24
expands to Stage 2, and the diagonal striped fill represents the probability of stopping
the trial early after Stage 1; i.e., the sample size required to achieve our desired pre-
dictive probability exceeds our pre-defined maximum sample size. Similar to previous
results, we do not observe a large benefit in the two-stage design when only one schedule
is acceptable. Here, we identify schedule 1 as better in 42.4% of all simulated trials with
a 5% increase after Stage 2. Scenarios 2 through 4 illustrate the advantage of our two-
stage approach. We are most likely to correctly identify Schedule 1 as the best schedule
in all cases, but we observe a larger benefit from our two-stage approach in Scenarios 3
and 4, when schedule 1 has a larger magnitude of immune response. In Scenario 3, we
see a 12% increase (from 41% to 53%) in correctly identifying Schedule 1 after Stage
2 while in Scenario 4, we see a 11.7% increase (from 46.3% to 58%). Finally, we note
that expanding to Stage 2 dramatically decreases the number of inconclusive results in
all cases, which illustrates the advantage of the two-stage approach.
2.5 Discussion
We have presented a Phase I-II trial design for therapeutic cancer vaccines. A unique
aspect of this design is that we are comparing vaccination schedules, rather than dose
levels, and there is neither a complete nor partial ordering of the vaccination schedules.
In this case, we consider a randomized design, where subjects are randomized to one
of two or more vaccination schedules, rather than a dose-escalation design, which is
the standard approach for Phase I clinical trials in oncology. Dose-escalation designs
are used in standard Phase I clinical trials in oncology for ethical reasons (i.e., it is
not ethical to treat subjects at higher dose levels when lower dose levels have not been
proven safe). In our setting, there are no ethical concerns about randomizing sub-
jects to a vaccination schedule because there is no a priori ordering of the schedules.
Randomization is the gold standard for comparing two treatment assignments, which
allows our design to make an unbiased comparison between the two schedules’ responses.
Our design uses a two-stage approach to evaluate and compare vaccination schedules.
In the first stage, we evaluate the rate of dose limiting toxicities and the immune re-
sponse rate and use these results to identify the set of acceptable vaccination schedules.
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Figure 2.1: Outcome frequency for determining the best schedule when comparing four
vaccination schedules. The white fill represents the outcome probabilities after the first
stage; the grey fill represents the improved outcome probabilities after the second stage.
In the “Inconcl.” bar, the diagonal fill represents the percent of trials that stop after
Stage 1 because the best schedule could not be determined using predictive probability
with the maximum sample size enrolled. True toxicity and immune response rates (and
magnitude) are displayed directly below each vaccination schedule.
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Ideally, we would be able to make a definitive statement as to the superiority of one
of the schedules after the first stage but, if this is not possible, we expand to a second
stage to complete a more precise comparison of the schedules. We use Bayesian predic-
tive probabilities to determine the sample size required to achieve a conclusive result
and the trial terminates for futility if we are unlikely to reach a definitive conclusion
with a pre-determined maximum sample size. Our simulation results show that our
two-stage approach dramatically reduces the number of inconclusive trials with only a
small increase in the expected sample size. Additional simulation results indicate simi-
lar performance when we generalize our design from two to four vaccination schedules
under evaluation.
We determine the superior vaccination schedule among acceptable schedules using the
magnitude of immune response at the suggestion of our clinical collaborators. We mod-
eled immune response as a zero-inflated log-normal distribution and expected immune
response as a function of both the immune response rate and the expected magnitude
of immune response for subjects conditional on a non-zero response. Other approaches
to identifying the best vaccination schedule could also be considered. For example, the
immune response rate could be used to identify the best schedule unless multiple ac-
ceptable schedules have 100% immune response, in which case magnitude of response
could be used to break the tie. Alternately, a formal decision theoretic approach could
be used to consider the trade-off between the rate of toxicity, immune response rate and
magnitude of response. We chose to proceed with our approach due to clinical relevance
but other approaches should also be investigated.
Typically, the outcomes of a Phase I-II clinical trial are dose-limiting toxicities and
tumor response, or some other measure of clinical outcome. In our case, we use the
same toxicity outcome but our efficacy outcome is immune response, rather than tu-
mor response. Immune response is an inexact surrogate for clinical response and a
subsequent Phase II trial would be needed to evaluate the clinical benefit of the best
vaccination schedule identified from this trial. Nevertheless, we feel that “Phase I-II” is
an accurate description of our proposed design because we are considering both a toxic-
ity and efficacy endpoint. Future work to incorporate both immune response and tumor
27
response could follow the approach of Zhong et al. (2012), who developed a trivariate
continual reassessment method for incorporating surrogate efficacy into dose-finding.
2.6 Supplementary Materials
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Chapter 3
Hierarchical Models for Sharing
Information Across Populations
in Phase I Dose-Escalation
Studies
3.1 Introduction
Researchers are often interested in evaluating the performance of a novel treatment in
multiple patient populations. In this case, investigators may be required to complete
multiple Phase I trials to determine the MTD for each population if the novel treatment
is to be used in combination with background standard-of-care that differs by popula-
tion. For example, results have recently been reported for Phase I clinical trials of
Veliparib, a novel PARP inhibitor, in combination with cyclophosphamide for patients
with solid tumors and lymphomas (Kummar et al., 2012), whole abdominal radiation
for patients with advanced solid malignancies and peritoneal carcinomas (Reiss et al.,
2015), whole brain radiation for patients with brain metastases (Mehta et al., 2015) and
cisplatin and etoposide in patients with small cell lung cancer (Owonikoko et al., 2015),
each resulting in a different estimated MTD.
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Completing separate Phase I trials for each patient population is expensive and time-
consuming, while collapsing across populations into a single trial would not be scien-
tifically justified. Furthermore, while it is reasonable to assume that the MTD will
vary by population, it is also likely that the results of a Phase I trial in one population
would provide information about the MTD in the other populations. This motivates
a hierarchical modeling (HM) approach that allows each patient population to have a
separate MTD but shares information across populations during dose-finding.
3.1.1 Hierarchical Modeling in Phase I Oncology Trials
HM is a widely used statistical approach for sharing information across populations
that has been applied to the analysis of clinical trials in a number of settings, including
meta-analysis, multi-center trials, multiple comparisons, variable selection, and sub-
group analysis (Sutton et al., 2000; Durbec and Sarles, 1978; George and McCulloch,
1993; Stangl, 1995). While HM has been used extensively in Phase III clinical trials,
the statistical literature for HM in early phase clinical trials (i.e. Phases I and II) is
limited. In Phase I dose-finding trials, HM has been used to pool information across
pharmacokinetic data from healthy volunteers (Patterson et al., 1999) and to improve
estimation of the probability of a DLT for combinations of doses of two therapeutic
agents (Braun and Wang, 2010). HM has been used more extensively in Phase II clini-
cal trials as an approach to properly model treatment response in the presence of disease
subpopulations (Berry et al., 2013; Thall et al., 2003) and to identify personalized cancer
treatments in genetically-defined subgroups, most notably in the BATTLE (Kim et al.,
2011) and I-SPY 2 trials (Barker et al., 2009).
This chapter discusses HM in the context of Phase I oncology trials. HM has been
used in Phase II and III clinical trials to facilitate the borrowing of information across
patient populations. Applying HM to Phase I oncology trials will allow borrowing of
information across populations but provide flexibility by specifying a different MTD for
each population. In addition, we also propose novel dose-finding guidelines for Phase
I clinical trials using HM. Standard dose-finding approaches that escalate in cohorts of
three will not take full the advantage of sharing information across populations, while
dose-adaptation after every patient will be too aggressive and jeopardize patient safety.
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The dose-finding guidelines proposed in Section 4.3 allow us to fully realize the potential
of HM in Phase I clinical trials, while achieving safety profiles similar to standard Phase
I trial designs.
The remaining sections of this chapter proceed as follows. First, Section 3.2 discusses
hierarchical extensions to three commonly used dose-toxicity models for the CRM. In
Section 3.3, we propose dose-finding guidelines and present our dose-finding algorithm
for Phase I oncology trials using HM. In Section 3.4, we present simulation results evalu-
ating the operating characteristics of the proposed design. Finally, Section 3.5 concludes
with a brief discussion of our findings and the potential for implementing the proposed
methods in practice.
3.2 Dose-Toxicity Models
In this section, we discuss hierarchical extensions of three commonly used dose-toxicity
models in Phase I clinical trials. In each case, we define a two-level, Bayesian hierarchical
model with population-specific effects that allows borrowing across populations. The
following notation will be used throughout this section. Let Yikj be a binary indicator for
a DLT in patient i = 1, . . . , nkj , in population k = 1, . . . ,K, at dose level j = 1, . . . , D.
Denote pikj(i) = Pr(Yikj = 1|Dose = j, Population = k) as the probability of a DLT
for patient i in population k treated at dose level j. Throughout the remainder of this
section, we drop the subscript for patient, i, for simplicity.
3.2.1 Power Model
The first model we consider is an extension of the power model presented by O’Quigley
and Shen (1996), which is a one-parameter dose-toxicity model commonly used in Phase
I oncology trials. We define our hierarchical power model as follows:
pikj = p
exp(αk)
j (3.1)
αk ∼ N(A, σ2)
A ∼ N(0, 22) and log(σ) ∼ Unif(−1, 1)
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Here, (p1, . . . , pD) is a monotonically increasing prior skeleton, which describes clini-
cians’ prior belief in the probability of a DLT at each dose level. The prior skeleton is
constant across populations and specified in advance. Note αk is the power parameter
for the kth population, A represents the shared mean and σ2 controls the degree of
borrowing across populations. From our prior specification, 99% of A’s prior mass falls
between -6 and 6, which allows the probability of a DLT to range from 0.01 to 0.99
regardless of 0 < pj < 1. This is a commonly used prior specification in traditional
dose-finding studies (Yin and Yuan, 2009; Liu et al., 2015). The uniform distribution
assumed for log(σ) is defined on (-1, 1) with a prior mean of 0 (Gelman et al., 2006).
Consequently, σ2 takes values in (0.14, 7.4). When σ2 is small, our model suggests
homogeneity across populations and encourages borrowing. In contrast, large values
for σ2 suggest heterogeneity across populations, resulting in less borrowing. Finally, we
note that the power model has been shown to be equivalent to the hyperbolic-tangent
model with a different dose transformation (O’Quigley and Shen, 1996; Paoletti and
Kramar, 2009).
3.2.2 Logistic Regression Model
An alternative one-parameter model is a logistic regression model with fixed intercept
(Goodman et al., 1995):
logit(pikj) = −3 + βk × qj , (3.2)
βk ∼ N(B, τ2)
B ∼ N(1, 22) and log(τ) ∼ Unif(−1, 1)
Here, we fix the intercept to be -3 corresponding to a 5% probability of a DLT by
chance, i.e., with no dose. Note βk is the slope parameter for the k
th population, B is
the shared mean slope and τ2 controls the degree of borrowing across populations. In
this model, (q1, . . . , qD) are scaled dose-levels that can be specified to reflect the inves-
tigator’s prior expectation for the probability of DLT at each dose. For the simulation
results presented in Section 3.4, we specified (q1, . . . , qD) such that the induced values
of pikj are equal to the prior skeleton used in Section 3.2.1 assuming a slope equal to
the prior mean of 1. Under our prior specification for B, 99% of B’s prior mass is
between -5 and 7, which allows our probability of a DLT to range from < 0.001 to
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1. In addition, we note that while we expect the slope βk to be positive, we choose a
normal prior for the slope, rather than an exponential or gamma prior, because we have
found the normal prior to result in better performance and because it results in a more
natural hierarchical extension to the standard model. As with the power model, the pa-
rameter controlling the amount of sharing, i.e. τ2’s distribution, is defined on (0.14, 7.4).
Originally, we also considered a two-parameter logistic regression model that allowed
each population’s dose-toxicity model to have a random intercept and slope. This model
required that we specify a bivariate normal model for the correlated intercept and slope.
We considered the conditionally-conjugate inverse-Wishart for the covariance prior, as
well as the more flexible decomposition prior, Σ = SRS, discussed by Barnard et al.
(2000). We found that this model is overly complex for the small sample sizes in Phase
I clinical trials and sensitive to prior input values. Furthermore, it did not improve
operating characteristics and it has been shown that the one-parameter logistic model
has better performance than the two-parameter logistic model in Phase I clinical trials
(Paoletti and Kramar, 2009). Therefore, the two-parameter logistic regression model
will not be considered further.
3.2.3 Curve-Free Model
The first two models are parametric and potentially vulnerable to model misspecifica-
tion. An alternate approach is a curve-free method that directly models the probability
of DLT at each dose-level while imposing a monotonicity constraint on the relationship
between dose and the probability of DLT without specifying a formal parametric form
for the dose-toxicity relationship (Gasparini and Eisele, 2000). Gasparini and Eisele
(2000) reparameterize the probability of DLT at each dose-level as follows:
{θ1 = 1− pi1, θ2 = (1− pi2)/(1− pi1), . . . , θD = (1− piD)/(1− piD−1)} .
The {θ1, . . . , θD} are then given independent priors. If we define θj to follow a Beta dis-
tribution, the induced joint distribution on the probabilities of DLT is a product-of-beta
prior (Gasparini and Eisele, 2000). Extending the product-of-beta prior to hierarchical
modeling is unclear and awkward. Instead, we specify our hierarchy on the θs after a
logit transformation to facilitate borrowing of information across populations.
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A hierarchical model for the curve-free method can be specified as follows:
logit(θkj) = γkj , (3.3)
γkj ∼ N(Γj , ν2j ),
Γj ∼ N(cj , 32) and log(νj) ∼ Unif(−1, 1),
where γkj is the unrestricted model parameter for population k and dose j, Γj is the
shared population mean for dose j and ν2j controls the amount of borrowing across
populations for each dose level j, j = 1, . . . , D. As with the logistic regression model
discussed in Section 3.2.2, the hyper-parameters (i.e., cj , j = 1, . . . , D) can be specified
such that they induce values of pikj equal to the prior skeleton used in Section 3.2.1.
This prior specification implies a 99% prior probability that Γj is within cj ± 9 for
j = 1, . . . , D and, again, the prior distribution for ν2j is defined on (0.14, 7.4).
The prior distributions discussed above represent the final priors used to fit these models
but other prior distributions, particularly for the hierarchical variance parameter, were
also considered. Specifically, we also considered the conditionally-conjugate inverse-
Gamma prior for the variance and a Uniform(0,b) prior on the standard deviation.
However, the former is sensitive to prior input values when the estimated standard
deviation is small, which can occur early in the trial or for homogeneous populations
(Gelman et al., 2006). A Uniform(0,b) prior on the standard deviation places more
density on more extreme prior σ2 values than the Uniform(-a, a) prior on the log stan-
dard deviation. As a result, convergence and identifiability are a concern with the small
sample sizes found in Phase I clinical trials.
3.3 Dose-Finding Algorithm
In this section, we discuss dose-finding when using hierarchical modeling to share infor-
mation across populations in Phase I oncology trials. We expect that enrollment will be
staggered and randomly distributed across patient populations with several consecutive
patients enrolled in one population, while long stretches may occur without enrolling
patients in others. As a result, extending standard Phase I dose-finding algorithms to
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our case is not trivial. Typically, Phase I dose-escalation studies use cohorts of three
patients and the MTD is re-evaluated for each new cohort. There are two natural exten-
sions of this approach but neither is satisfactory. First, we could re-evaluate the MTD
after each cohort of three patients, regardless of patient population. This approach
would be too aggressive and could result in a patient being treated at a higher dose
level before lower dose levels had have been tried in that patient’s population. The
second option would be to use cohorts of three patients within a patient population and
only re-evaluate the MTD within a patient population when a new cohort is ready to
enroll. This approach would be too conservative, failing to take full advantage of HM
and treat too many patients at sub-therapeutic dose levels. Therefore, we propose three
dose-finding guidelines (DFGs) and compare the performance of each through simula-
tion.
Throughout the rest of this section, we select the MTD and terminate the trial for
excess toxicity as follows. Let piT be a pre-defined target toxicity rate. Dose-level j in
population k is considered to have acceptable toxicity if:
Pr(pikj < piT |Data,Dose) > γ. (3.4)
This is a commonly used criterion in Phase I oncology trials and γ is typically chosen
between 0.05 and 0.20. The threshold γ can be thought of as a tuning parameter, which
is chosen to achieve the desired operating characteristics for the trial (Berry et al.,
2010). Alternately, γ can be considered as the acceptable amount of error, since a dose
is only declared unacceptable when the posterior distribution strongly suggests it is
overly toxic. We have defined piT and γ to be constant across populations but these
could be made population-specific, if desired. In the context of the DFGs described
below, the MTD for population k, MTDk, is defined as the dose-level that minimizes
the absolute difference between the probability of a DLT and piT from among the set
of doses with acceptable toxicity. Dose-finding for a population terminates if the lowest
dose-level has unacceptable toxicity by Criterion (3.4).
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3.3.1 Dose-Finding Guidelines
We now describe three DFGs for Phase I clinical trials with multiple patient popula-
tions. In each DFG, initial patients in each population start at the lowest dose-level.
The DFGs define when it is acceptable to escalate, at which point dose assignment will
depend on the estimated MTDk for each population k = 1, . . . ,K using the hierarchical
models described in Section 3.2.
The most common approach to dose-finding in Phase I oncology trials is to escalate
in cohorts of three patients. The first approach we consider is to allow escalation within
a population when at least 3 patients have been treated across all populations and at
least 1 patient has been treated in the current population. We refer to this approach
as the “1(m)” DFG. Here, we describe our DFGs in terms of a general cohort size, m,
to allow for additional flexibility as cohort sizes of two and four patients have also been
proposed for Phase I oncology trials. Formally, the “1(m)” DFG allows escalation to
dose-level j + 1 for population k = 1, . . . ,K if:
• m patients overall (and at least 1 patient in population k) have been treated at
dose level j.
We note that a special case of the “1(m)” DFG occurs when all m patients previously
treated at dose-level j are in population k, which would allow escalation and is con-
sistent with the standard Phase I design that escalates in pre-specified cohorts of size
m. For example, if m = 3, the “1(m)” DFG allows the fourth patient enrolled, say
in population k, to potentially escalate to dose-level 2 as long as one of the first three
patients treated at dose-level 1 was in population k. This suggests observing m patients
within a population is equivalent to observing m patients overall in estimating each
population’s dose-response curve.
It is possible that the “1(m)” DFG might be too aggressive and result in an unac-
ceptably high number of toxicities. Therefore, we consider two other DFGs with further
restrictions to protect patient safety. First, we consider the “m/1(m + 1)” DFG. The
“m/1(m+1)” DFG allows escalation to dose-level j + 1 for population k = 1, . . . ,K if:
• m patients in population k have been treated at dose level j,
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• Or m + 1 patients overall (and at least 1 patient in population k) have been
treated at dose level j.
For m = 3, the “m/1(m + 1)” DFG allows dose escalation in population k if m = 3
patients in population k have been treated at population k’s current dose level or if
m + 1 = 4 patients overall have been treated at population k’s current dose level with
at least one patient in population k. This suggests observing m patients within a pop-
ulation is equivalent to observing m+ 1 patients overall in informing our dose-response
models.
Finally, we propose a third DFG, which we refer to as the “321” DFG, which is similar
to the “m/1(m+ 1)” DFG but puts additional restrictions on escalation to protect pa-
tient safety and promote reasonable sharing across populations. The “321” DFG allows
escalation to dose-level j + 1 for population k = 1, . . . ,K if:
• 3 patients in population k have been treated at dose-level j,
• OR 2 patients in population k and at least 2 patients not in population k have
been treated at dose-level j,
• OR 1 patient in population k and at least 1 patient in three other populations
have been treated at dose-level j.
The “321” DFG is the most restrictive of the three DFGs. Examples of scenarios where
the “m/1(m+ 1)” DFG would allow escalation to dose-level j + 1 but the “321” would
not include:
• only 1 patient in population k and 3 patients in population k2 have been treated
at dose level j,
• only 1 patient in population k, 2 patients in population k2 and 1 patient in pop-
ulation k3 have been treated at dose level j.
The “321” DFG restricts the scenarios where escalation is allowed after only one pa-
tient in a population has been treated at the current dose-level to reduce the influence
of other populations’ estimated dose-response curves, should they be different. While
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this restriction slows dose-finding by requiring more patients to enroll, it is incorporated
for patient safety.
Figures 3.1 through 3.4 below present a single simulated trial using the three DFGs
described above, along with a trial with no restrictions on escalation except that un-
tried dose-levels cannot be skipped when escalating within a population (no DFG). We
note that the DFGs defined above indicate when it is potentially acceptable to escalate
to an untried dose within a population but the ultimate decision to escalate will be
based on the current estimate of the MTDk using all available data. In some sense, the
DFGs define a run-in period for each population and dose-level to prevent escalation
without sufficient evidence that the current dose-level is safe within each population.
In summary, our dose-finding algorithm for identifying each MTDk for k = 1, . . . ,K
in a Phase I clinical trial using HM proceeds as follows:
1. Treat the first patient within each population at the lowest dose level.
2. When a new patient is enrolled, update the posterior distribution of the probability
of toxicity for all dose-levels and populations using all available data.
3. Identify the set of acceptable doses for each population using Criterion (3.4).
4. If all doses are unacceptably toxic and at least 3 patients have been treated in
the current population, then the trial terminates for that population. For each
population, if all doses are unacceptably toxic but less than 3 patients have been
treated in that population, then the next patient is treated at dose-level 1.
5. Otherwise, treat the next patient at the dose-level that minimizes |E(pikj |Data)−
piT | from among the acceptable dose-levels under the restriction that escalation
is only allowed if the criterion for escalation is satisfied for the pre-specified DFG
and escalating more than one dose-level at a time is not allowed.
6. Repeat steps 2-5 until the maximum overall sample size is reached. Within each
population, the acceptable dose that minimizes |E(pikj |Data)−piT | at study com-
pletion is considered the MTDk for k = 1, . . . ,K.
47
3 9 12 2 34 36 1 7 19 21 5
13 15 16 23 35
18 24 26
28 38
22 37 39 4 30 40 8 14 25 6
43 31 32 33
41
10 20 45 11 27 29 42
17 44
D
os
e 
4
D
os
e 
3
D
os
e 
2
D
os
e 
1
Est.MTD 1 1 2 2 4
True MTD 0 1 2 3 4
Group 1 Group 2 Group 3 Group 4 Group 5
Patient Number
DLT
Figure 3.1: no DFG: Display of dose-finding for a simulated trial when no DFGs are
implemented in our dose-finding algorithm. White circles display the patient number;
grey circles depict if the patient experienced a DLT. The true MTDk is displayed at the
top of the figure, directly below each population; the estimated MTDk is displayed at
the bottom of the figure for each population.
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Figure 3.2: 1(m): Display of dose-finding for the same simulated trial when the “1(m)”
DFGs are implemented in our dose-finding algorithm. White circles display the patient
number; grey circles depict if the patient experienced a DLT; bolded circles represent
if dose-escalation is allowed for any of the populations after patient enrollment. The
true MTDk is displayed at the top of the figure, directly below each population; the
estimated MTDk is displayed at the bottom of the figure for each population.
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Figure 3.3: m/1(m+1): Display of dose-finding for the same simulated trial when
the “m/1(m+1)” DFGs are implemented in our dose-finding algorithm. White circles
display the patient number; grey circles depict if the patient experienced a DLT; bolded
circles represent if dose-escalation is allowed for any of the populations after patient
enrollment. The true MTDk is displayed at the top of the figure, directly below each
population; the estimated MTDk is displayed at the bottom of the figure for each
population.
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Figure 3.4: 321: Display of dose-finding for the same simulated trial when the “321”
DFGs are implemented in our dose-finding algorithm. White circles display the patient
number; grey circles depict if the patient experienced a DLT; bolded circles represent
if dose-escalation is allowed for any of the populations after patient enrollment. The
true MTDk is displayed at the top of the figure, directly below each population; the
estimated MTDk is displayed at the bottom of the figure for each population.
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We note that, in step 4, only the most recently enrolled and treated population can
terminate for excess toxicity (i.e., a population cannot terminate based on an outcome
in another population). In addition, we do not force balance across populations by
specifying a maximum number of subjects per population. Enforcing balance would
likely improve the operating characteristics of the trial but would also dramatically
increase the duration of the trial. Our dose-finding algorithm proposes to update the
joint posterior for all populations after every patient. We also explored an approach
where the model is only updated when the enrolled population is permitted to dose-
escalate. The only practical difference between the two approaches is that we allow
de-escalation regardless of whether or not a population is allowed to escalate according
to the DFG. We feel that this is appropriate because it is always preferable to treat
patients at the current estimate of the MTD and only place restrictions on escalation
to protect patient safety, which is not a concern when de-escalating. The operating
characteristics of this design were very similar to the proposed algorithm.
3.4 Simulation Study
We conducted a simulation study to evaluate the operating characteristics of a Phase I
clinical trial using the hierarchical models and DFGs described in Sections 3.2 and 3.3.
We evaluate the performance of each method based on (i) the probability of correctly
identifying each MTDk, (ii) the percent of patients experiencing a DLT, (iii) the percent
of patients treated at each MTDk and (iv) the percent of patients treated above each
MTDk for k = 1, . . . ,K. Trial parameters were set as follows. We assume a maximum
of 45 patients across K = 5 populations and assume an equal probability of enrollment
to each population (i.e., an average of 9 patients/population). The target toxicity rate
was set to piT = 0.3. The threshold for determining if a dose has an acceptable proba-
bility of toxicity, γ, was set equal to 0.2. We consider D = 4 dose levels with dose index
{1, 2, 3, 4}. All simulations were completed in R version 3.1.1. Gibbs and slice sampling
were completed in JAGS via R using rjags (Plummer, 2011). Posterior inference was
completed using 10,000 MCMC samples following a period of 5,000 iterations for burn-
in. 1000 simulated trials were completed for each scenario.
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The skeleton for the power model, (p1, . . . , p4), was set equal to (0.1, 0.2, 0.35, 0.50).
The scaled dose-levels for the logistic regression model, (q1, . . . , q4), were set equal to
(logit(0.1) + 3, logit(0.2) + 3, logit(0.35) + 3, logit(0.5) + 3) to achieve a prior skeleton
for the probability of toxicity equal to the power model skeleton assuming a slope equal
to the prior mean of 1 (Sweeting et al., 2013). We similarly set the hyper-parameters for
the curve-free method, (c1, . . . , c4), equal to (1, 1.5, 2, 2.5), which induces (pik1, . . . , pik4)
equal to the power model skeleton.
In addition to simulating a Phase I clinical trial using the models and DFGs described
in Sections 3.2 and 3.3, we also evaluated the operating characteristics of three other
designs, for comparison. First, we considered a Phase I clinical trial using hierarchical
modeling that treats each patient at the current estimate of each MTDk with no restric-
tions on dose-escalation other than untried dose-levels within a population cannot be
skipped when escalating (no DFG). The DFGs described in Section 3.3 were proposed,
primarily, to protect patient safety and a comparison to a design with no restrictions on
dose-finding will allow us to isolate the impact of the dose-finding guidelines on the var-
ious operating characteristics of the trial. In addition, we simulated two types of Phase
I designs that did not use hierarchical modeling and fit independent models for each
population. For these two designs, we fit the models specified in Section 3.2 without
the second level of the hierarchy and specified independent N(0, 22) priors for the αks,
independent N(1, 22) priors for the βks and independent N(cj , 3
2) for the γjks with cj
as specified in the previous paragraph. For the independent models, we considered a
design with a maximum sample size of 45 patients and a design with a maximum sample
size of 90 patients, both with dose-adaptation occurring after every patient. This will
allow us to evaluate the benefit of using HM, as compared to designs that treat each
population as independent data.
3.4.1 Scenarios
We simulated data from the six scenarios presented in Figure 3.5. The true dose-response
curves were set by specifying the slope and MTD in a logistic regression model, with the
exception of Group 5 in Scenario 6, which is taken to be qualitatively different from the
other groups. In Scenario 1 (top, left plot), all five groups have the same dose-toxicity
53
curve and the optimal design would be to collapse the five groups and complete a single
trial assuming a common dose-toxicity curve for all groups. In Scenario 2 (top, right
plot), all five groups have the same MTD but different dose-toxicity curves. Scenarios 3
(middle, left plot) and 4 (middle, right plot) represent scenarios where the dose-toxicity
curves vary by population with true MTDs ranging from dose 1 to dose 4 in Scenario
3 and dose 1 to dose 3 in Scenario 4. Scenario 4 was suggested to us by a researcher
in the field as a particularly difficult case that we would expect to see in practice. In
Scenario 5 (bottom, left plot), all doses are unacceptably toxic for group 1, while dose
1 is the MTD for the second and third groups and dose 2 is the MTD for the last two
groups. Finally, in Scenario 6 (bottom, right plot) all doses are unacceptably toxic for
group 1, while each of the other four groups has a different MTD.
3.4.2 Results
Figure 3.6 presents the probability of correctly identifying each MTDk and the percent
of patients experiencing a DLT for Scenarios 1 through 3 using the power model. Results
for Scenarios 4 through 6 can be found in Figure 3.9 in Section 3.6. In Scenario 1, all
groups have the same dose-toxicity curve, while in Scenario 2, all groups have the same
MTD but different dose-toxicity curves. We see that, in both scenarios, the hierarchical
modeling approach results in a higher probability of correctly identifying each MTDk
than the independence model with a maximum sample size of 45 subjects regardless of
the DFG. We note that this is a relatively high bar in that the independence model
with 45 patients allows adaptation after every subject and does not include the typical
restrictions (cohorts of 3, etc.) that are put in place to protect patient safety but may
decrease the probability of correctly identifying the MTD. In addition, the hierarchical
power model does as well as, or better than in some cases, than the independence design
with 90 patients. This indicates that, in Scenarios 1 and 2, hierarchical modeling was
as valuable as doubling the maximum sample size from 45 to 90 patients in independent
designs. In Scenarios 3 through 6, where the MTD varies across groups, the hierarchi-
cal approach improves upon the independence model with a maximum sample size of
45 in most cases, with the exception of Group 1 in Scenarios 5 and 6 and Group 5 in
Scenarios 3 and 6. These are scenarios where either all of the doses were unacceptably
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Figure 3.5: Scenario 1 (top, left): all populations’ dose-response curve are equivalent.
Scenario 2 (top, right): all populations have the same MTD level, but slope increases
with population index. Scenario 3 (middle, left): the MTD for each population is
dispersed across all four dose-levels for the five populations. Scenario 4 (middle, right):
the first three populations’ MTD is dose level 1; the last two populations have MTD at
dose level 2 and 3, respectively. Scenario 5 (bottom, left): population 1 terminates trial;
the next two populations’ MTD is dose level 1 the last two populations’ MTD is dose
level 2. Scenario 6 (bottom, left): similar to Scenario 4, except population 1 terminates
trial. The MTD for each population is identified with an asterisk.
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toxic or where dose 4 was the MTDk, suggesting that the hierarchical model was in-
correctly shrinking the estimated MTDk towards intermediate doses due to the results
of the other populations. Finally, we note that the three hierarchical DFGs correctly
identified each MTDk at a similar rate as the hierarchical model with no DFG. The goal
of implementing the DFGs was to protect patient safety and it is encouraging to see
that the three DFGs did not adversely impact the probability of correctly identifying
each MTDk.
Our initial results indicate that HM increases the probability of correctly identifying
each MTDk but a potential concern related to the implementation of this approach is
that HM would increase the number of DLTs due to sharing information across popu-
lations. Our results suggest that HM does not substantially increase the rate of DLTs
and, in fact, results in a decreased probability of DLT relative to the independence
designs, in most cases, with the only exceptions occurring when the lowest dose is the
MTD for one population but the MTD is higher for other populations. In this case,
HM shrinks the estimated MTDk towards intermediate dose-levels due to the results
for the other populations, although even in these cases, the increase in the DLT rate is
minor. In addition, we note that our results present the percent of patients experiencing
a DLT, rather than the absolute number of DLTs, which implies that the independence
model with a maximum sample size of 90 subjects will have a much larger total num-
ber of DLTs than the HM designs. Therefore, while the independence design with 90
patients is more likely to accurately identify each MTDk, in some cases, this comes at
the expense of a dramatically higher number of DLTs. Finally, while the differences are
subtle, we note that the “321” DFG results in fewer DLTs than the “m/1(m+1)” DFG,
which in turn results in fewer DLTs than the “1(m)” DFG, as expected.
Figures 3.10 and 3.11 in Section 3.6 present the average number of patients treated
at each MTDk and the average number of patients treated above each MTDk. Our re-
sults indicate that in addition to increasing the probability of correctly identifying each
MTDk and decreasing the rate of DLTs, HM increases the average number of subjects
treated at each MTDk and decreases the number of patients treated at unsafe doses
above each MTDk, in many cases. Again, exceptions to this rule occur when the lowest
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Figure 3.6: Power Model: Scenarios 1-3(left plots): Probability of correctly identifying
the true MTD; Scenario 1-3 (right plots): The percent of patients experiencing a DLT
for each population. Results from 1000 simulated trials are displayed for “no DFG” and
the three proposed DFGs: “1(m)”, “m/1(m+1)” and “321” (with max 45 patients), and
K independent models assuming different maximum sample sizes (45 and 90 patients
overall), displayed in parenthesis.
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dose is the MTD or when all doses are excessively toxic. In this case, the independence
design treats fewer patients above the true MTDk due to its propensity to stop the
trial early and declare all doses overly toxic. We note that results for the independence
design with a maximum sample size of 90 subjects were not included in these results
because the larger sample size skews our results with respect to the y-axis and because
the larger design results in a substantial increase in DLTs compared to the HM designs.
Figure 3.7 and Figures 3.12 through 3.14 in Section 3.6 present results using the hi-
erarchical logistic regression model. Similar to the power model, the logistic regression
model performs well when the populations exhibit homogeneity with regards to the
MTD (Scenarios 1 and 2), identifying each MTDk as often as the independence design
with a maximum sample size of 90 subjects. Unlike the power model, the hierarchical
logistic regression model performed poorly when the MTD varied by population, with
particularly poor performance in Scenarios 5 and 6, identifying each MTDk no more
often, and in many cases less often, than the design that assumes independence. Fur-
thermore, we see that, in many cases, the hierarchical logistic regression model treated
no more, and in some cases less, patients at the true MTDk than the independence mod-
els, although we note that the logistic regression model was more likely to under-dose.
Finally, results for the hierarchical curve-free model can be found in Figure 3.8 and
Figures 3.15 through 3.17 in Section 3.6. This model is non-parametric and thus richly
parameterized compared to the other two models. When the groups are homogeneous,
we see the HM designs out-perform the two independence designs. On the other hand,
the hierarchical curve-free model performed very poorly in some cases. In particular,
the hierarchical curve-free model was unlikely to properly identify the MTD5 for Group
5 in Scenarios 3, 4 and 6. In these cases, Group 5 had a higher MTD5 than the other
groups and the hierarchical component of the model shrank the estimated MTD5 to-
wards intermediate doses and underestimated the MTD. In addition, this model also
performed poorly when all doses were excessively toxic (Group 1 of Scenarios 5 and 6).
In a sense, these results are to be expected for this model. In Scenarios 1 and 2, where
the populations are homogeneous and the model borrows strengths across groups, the
added flexibility of the curve-free method results in a very high probability of correctly
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Figure 3.7: Logistic Regression Model: Scenarios 1-3(left plots): Probability of
correctly identifying the true MTD; Scenario 1-3 (right plots): The percent of patients
experiencing a DLT for each population. Results from 1000 simulated trials are displayed
for “no DFG” and the three proposed DFGs: “1(m)”, “m/1(m+1)” and “321” (with
max 45 patients), and K independent models assuming different maximum sample sizes
(45 and 90 patients overall), displayed in parenthesis.
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identifying each MTDk. In contrast, when the populations are heterogeneous and there
is little borrowing, the model is over-parameterized and is not able to accurately esti-
mate each MTDk.
In summary, our simulation results suggest that implementing HM in Phase I oncology
trials increases the probability of correctly identifying each MTDk by borrowing infor-
mation across populations. In addition, HM increases the number of patients treated at
each MTDk, decreases the percent of patients treated at unsafe dose-levels above each
MTDk and decreases the number of toxicities, in most cases. All three models borrowed
strength when the MTD was constant across populations, resulting in a more precise
estimate of each MTDk, but the hierarchical power model was more flexible and exhib-
ited better performance when the populations were heterogeneous. In addition, all three
DFGs achieve the stated goal of increased patient safety by restricting dose-escalation
but the “321” exhibited the best performance with limited impact on the probability of
correctly identifying each MTDk.
3.4.3 Exploring Other K
Our simulation used five populations to evaluate the operating characteristics of a Phase
I clinical trial using HM with the models and DFGs specified in Sections 3.2 and 3.3.
We now present additional simulation results to evaluate the impact of varying K and
determine the minimum number of populations needed to observe a benefit from using
HM. Simulation results are presented for K = 2, 3, 4 and we only considered the hier-
archical power model due to its superior performance in our initial simulation results.
The “321” DFG was used for K = 4 but is inappropriate for K < 4, so results for
K = 2 and K = 3 are presented for the “m/1(m+1)” DFG, instead. Simulations were
completed using the prior distributions specified in Section 3.2. However, performance
could potentially be improved by reducing the prior domain specified for σ. This is not
unreasonable, since we have fewer populations and therefore do not need as large of a
domain for σ to produce the appropriate amount of smoothing. Finally, our simulation
results assume a maximum sample size of 18, 27, 36 patients for K equal to 2, 3 and 4,
respectively, to achieve an average sample size of 9 patients per population, similar to
our results with K = 5.
60
Group1 Group2 Group3 Group4 Group5
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Scenario 1
Group1 Group2 Group3 Group4 Group5
0.
0
0.
1
0.
2
0.
3
0.
4
0.
5
no DFG
1(m)
m/1(m+1)
321
Ind.(45)
Ind.(90)
Group1 Group2 Group3 Group4 Group5
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Scenario 2
Tr
ue
 M
TD
 S
el
ec
tio
n 
P
ro
ba
bi
lit
y
Group1 Group2 Group3 Group4 Group5
0.
0
0.
1
0.
2
0.
3
0.
4
0.
5
P
er
ce
nt
 D
LT
s
Group1 Group2 Group3 Group4 Group5
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Scenario 3
Group1 Group2 Group3 Group4 Group5
0.
0
0.
1
0.
2
0.
3
0.
4
0.
5
Figure 3.8: Curve-Free Model: Scenarios 1-3(left plots): Probability of correctly
identifying the true MTD; Scenario 1-3 (right plots): The percent of patients experi-
encing a DLT for each population. Results from 1000 simulated trials are displayed for
“no DFG” and the three proposed DFGs: “1(m)”, “m/1(m+1)” and “321” (with max
45 patients), and K independent models assuming different maximum sample sizes (45
and 90 patients overall), displayed in parenthesis.
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Simulation results for 1000 simulated trials per scenario are presented in Table 3.1.
We present the probability of correctly identify each MTDk. The true dose-response
curves for K = 2, 3, 4 represent a subset of the dose-response curves used in the cor-
responding scenario for K = 5 in Section 3.5. We note that population indices may
change across K = {2, 3, 4} but the K = 5 population index is reported within each
scenario and K. For comparison, we simulated an independence design with 9 patients
per population for each scenario and K. This design allowed dose-escalation after each
patient under the restriction that no untried dose-levels be skipped when escalating,
which we reiterate represents a high bar because this design would typically use cohorts
of three patients (and a larger sample size), in practice.
We see that, in general, the probability of correctly identifying each MTDk increases
with K. Furthermore, we see that there is a clear advantage to HM with K = 4 but
that the probability of correctly identifying each MTDk was lower with the HM design
than with the independence design with K = 2 due to the increased complexity of
the hierarchical power model. With K = 3, HM increased the probability of correctly
identifying each MTDk, in most cases, but performed particularly poorly in Scenario 6,
where there was substantial heterogeneity in the MTDs across populations. Based on
these results, we recommend that HM in Phase I clinical trials be implemented with
a minimum of 3 populations but 4 populations are likely required to fully realize the
advantages of HM.
3.5 Discussion
We discussed HM for sharing information across populations in Phase I clinical tri-
als. First, we presented hierarchical extensions to three, commonly used dose-toxicity
models for Phase I oncology trials. These models allow for a different MTD in each
population, while borrowing strength across populations, when appropriate, to achieve
a more precise estimate of each population’s MTD. We then proposed three DFGs for
Phase I clinical trials using HM. The proposed DFGs allow us to take full advantage
of HM while protecting patient safety by restricting dose escalation until it has been
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shown that the current dose-level has an acceptable toxicity profile. Our simulation
results suggest that all three models are able to borrow strength when the MTDs are
constant across populations, resulting in a more precise estimate of each population’s
MTD, but the hierarchical power model is more robust when the populations are more
heterogeneous. In addition, we found that the “321” DFG provided the best trade-off
for estimating each population’s MTD while protecting patient safety of the three DFGs
considered. Finally, our simulation results suggest that HM would be beneficial with
as few as three populations but independent designs are more effective with only two
populations.
Returning to our motivating example of completing multiple, independent Phase I trials
to evaluate a single agent in multiple populations with different background standards-
of-care, our results are clear: completing independent designs for each population is not
the optimal approach and parallel designs while using HM to share information across
populations is more efficient. Our results indicate that in most cases the HM approach
results in an increased probability of correctly identifying each population’s MTD and
an increased number of patients treated at each population’s MTD while decreasing the
percent of patients experiencing DLTs and the number of patients treated at unsafe
doses above each population’s MTD. This provides a strong theoretical basis for pursu-
ing this type of design but additional work is needed to identify the practical challenges
related to implementing this approach.
We have presented the results of this chapter as an extension of the CRM, but the
method discussed in Section 3.2 can be applied to Bayesian adaptive Phase I designs
more broadly. Some clinicians remain hesitant to implement the CRM due to concerns
about escalating too quickly, resulting in excess DLTs. We proposed three DFGs to
protect patient safely, with the “321” algorithm exhibiting the best performance, and
our results indicate that HM actually results in fewer DLTs than independent CRM
designs. Nevertheless, other modifications to protect patient safety could also be con-
sidered. For example, Faries (1994) suggests always choosing the highest dose below
the current estimate of the MTD. Alternately, the EWOC (escalation with overdose
control) was proposed as an approach to limit DLTs in Phase I clinical trials (Babb
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et al., 1998), while Neuenschwander et al. (2008) propose classifying the posterior prob-
ability of a DLT into four categories: under-dosing, targeted toxicity, excessive toxicity,
and unacceptable toxicity, and using these probabilities to guide dose-finding. The
aforementioned approaches represent changes to the dose-finding algorithm and not the
dose-toxicity model. As a result, these methods could easily be integrated with HM to
achieve the benefits of borrowing information across populations while further limiting
DLTs.
Our simulation results presented in Section 3.4 depend on the prior distributions and
prior dose-response skeletons discussed in Section 3.2. We considered a variety of prior
input values and different prior distributions for our variance parameters, however, we
found the general trends to be consistent. Increasing the domain for our smoothing
parameter resulted in substantially improved performance when the populations are
homogeneous but much worse performance when the populations are heterogeneous.
We calibrated the hyperparameters for the hierarchical logistic regression and curve-
free method to be consistent with the prior skeleton used in the hierarachical power
model. While the hierarchical power model proved to be superior in this case, other
skeletons might be more appropriate for the other two models. However, we expect
that the non-ideal pooling behavior observed in the hierarchical logistic regression and
curve-free models would be similar regardless of the skeleton. Furthermore, the stan-
dard power model is often used with the CRM and we believe that practitioners might
be more familiar with specifying the power model skeleton than the corresponding pa-
rameters in the other models, which also supports the use of the hierarchical power
model.
Phase I dose-escalation designs, like the CRM, attempt to identify the MTD under
the assumption that the maximum dose that can be given safely is also the best choice
for identifying an efficacious dose. In practice, it is often the case that the efficacy of a
treatment may plateau or even diminish as dose increases, while potential toxicity is ex-
pected to increase monotonically with dose. This motivates the use of Phase I-II designs
that consider both efficacy and toxicity during dose-finding. These designs often rely
on a parametric model for the dose-response relationship for efficacy and toxicity and
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it would be worthwhile to investigate whether HM would be beneficial in this scenario,
as well.
3.6 Supplementary Materials
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Figure 3.9: Power Model: Scenarios 4-6(left plots): Probability of correctly identifying
the true MTD; Scenario 4-6(right plots): The percent of patients experiencing a DLT
for each population. Results from 1000 simulated trials are displayed for “no DFG” and
the three proposed DFGs: “1(m)”, “m/1(m+1)” and “321” (with max 45 patients), and
K independent models assuming different maximum sample sizes (45 and 90 patients
overall), displayed in parenthesis.
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Figure 3.10: Power Model: Scenarios 1-3(left plots): Average number of patients
treated at the true MTD; Scenario 1-3(right plots): Average number of patients treated
above the true MTD. Results from 1000 simulated trials are displayed for “no DFG”
and the three proposed DFGs: “1(m)”, “m/1(m+1)” and “321” (with max 45 patients),
and K independent model assuming a maximum sample sizes of 45 patients, displayed
in parenthesis.
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Figure 3.11: Power Model: Scenarios 4-6(left plots): Average number of patients
treated at the true MTD; Scenario 4-6(right plots): Average number of patients treated
above the true MTD. Results from 1000 simulated trials are displayed for “no DFG”
and the three proposed DFGs: “1(m)”, “m/1(m+1)” and “321” (with max 45 patients),
and K independent model assuming a maximum sample sizes of 45 patients, displayed
in parenthesis.
69
Group1 Group2 Group3 Group4 Group5
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Scenario 4
Group1 Group2 Group3 Group4 Group5
0.
0
0.
1
0.
2
0.
3
0.
4
0.
5
no DFG
1(m)
m/1(m+1)
321
Ind.(45)
Ind.(90)
Group1 Group2 Group3 Group4 Group5
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Scenario 5
Tr
ue
 M
TD
 S
el
ec
tio
n 
P
ro
ba
bi
lit
y
Group1 Group2 Group3 Group4 Group5
0.
0
0.
1
0.
2
0.
3
0.
4
0.
5
P
er
ce
nt
 D
LT
s
Group1 Group2 Group3 Group4 Group5
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Scenario 6
Group1 Group2 Group3 Group4 Group5
0.
0
0.
1
0.
2
0.
3
0.
4
0.
5
0.
6
Figure 3.12: Logistic Regression Model: Scenarios 4-6(left plots): Probability of
correctly identifying the true MTD; Scenario 4-6(right plots): The percent of patients
experiencing a DLT for each population. Results from 1000 simulated trials are displayed
for “no DFG” and the three proposed DFGs: “1(m)”, “m/1(m+1)” and “321” (with
max 45 patients), and K independent models assuming different maximum sample sizes
(45 and 90 patients overall), displayed in parenthesis.
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Figure 3.13: Logistic Regression Model: Scenarios 1-3(left plots): Average number
of patients treated at the true MTD; Scenario 1-3(right plots): Average number of
patients treated above the true MTD. Results from 1000 simulated trials are displayed
for “no DFG” and the three proposed DFGs: “1(m)”, “m/1(m+1)” and “321” (with
max 45 patients), and K independent model assuming a maximum sample sizes of 45
patients, displayed in parenthesis.
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Figure 3.14: Logistic Regression Model: Scenarios 4-6(left plots): Average number
of patients treated at the true MTD; Scenario 4-6(right plots): Average number of
patients treated above the true MTD. Results from 1000 simulated trials are displayed
for “no DFG” and the three proposed DFGs: “1(m)”, “m/1(m+1)” and “321” (with
max 45 patients), and K independent model assuming a maximum sample sizes of 45
patients, displayed in parenthesis.
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Figure 3.15: Curve Free Model: Scenarios 4-6(left plots): Probability of correctly
identifying the true MTD; Scenario 4-6(right plots): The percent of patients experienc-
ing a DLT for each population. Results from 1000 simulated trials are displayed for
“no DFG” and the three proposed DFGs: “1(m)”, “m/1(m+1)” and “321” (with max
45 patients), and K independent models assuming different maximum sample sizes (45
and 90 patients overall), displayed in parenthesis.
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Figure 3.16: Curve Free Model: Scenarios 1-3(left plots): Average number of patients
treated at the true MTD; Scenario 1-3(right plots): Average number of patients treated
above the true MTD. Results from 1000 simulated trials are displayed for “no DFG”
and the three proposed DFGs: “1(m)”, “m/1(m+1)” and “321” (with max 45 patients),
and K independent model assuming a maximum sample sizes of 45 patients, displayed
in parenthesis.
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Figure 3.17: Curve Free Model: Scenarios 4-6(left plots): Average number of patients
treated at the true MTD; Scenario 4-6(right plots): Average number of patients treated
above the true MTD. Results from 1000 simulated trials are displayed for “no DFG”
and the three proposed DFGs: “1(m)”, “m/1(m+1)” and “321” (with max 45 patients),
and K independent model assuming a maximum sample sizes of 45 patients, displayed
in parenthesis.
Chapter 4
Efficacy/Toxicity Dose-Finding
Using Hierarchical Modeling for
Multiple Populations
4.1 Introduction
Phase I oncology trials are primarily dose-escalation studies to evaluate the safety of a
novel treatment and identify the maximum tolerable dose (MTD), defined as the high-
est dose with probability of dose limiting toxicity (DLT) less than some pre-specified
threshold. Typically, the efficacy of the new treatment is not examined until Phase II.
The rationale for this approach is that clinicians have historically believed the prob-
abilities of toxicity and treatment efficacy increase monotonically with dose and, as a
result, the highest dose with acceptable toxicity was thought to have the best chance to
succeed in future Phase II and III clinical trials. However, for contemporary biologically
targeted agents, investigators often believe a drug’s potential efficacy may level off or
even diminish before reaching the MTD, while potential toxicity continues to increase
with dose. This motivates dose-finding trials based on the simultaneous evaluation of
toxicity and efficacy. Furthermore, given the limited sample sizes in Phase I oncology
trials, incorporating efficacy into dose-finding may help to better identify the optimal
dose used in subsequent Phase II and III clinical trials. In response, numerous Phase I-II
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trial designs have been proposed that incorporate efficacy and toxicity into dose finding.
Gooley et al. (1994) were among the first to propose a dose-finding design based on si-
multaneous evaluation of toxicity and efficacy. Their results suggest that the additional
dose-response curve for efficacy adds complexity to the dose selection algorithm. This
suggests a need to consider the cost of additional model parameters (i.e., the response
probability) when designing a Phase I-II trial. Consequently, Thall and Russell (1998)
propose a design that combines toxicity and efficacy into one variable, thereby reducing
the parameter space. Alternatively, Braun (2002) extends the continual reassessment
method to account for two competing outcomes, while Thall and Cook (2004) take a
similar approach but also define an efficacy/toxicity trade-off contour that can be used to
guide dose-finding. A number of extensions to this basic approach have been discussed
in the literature over the last decade (Yin et al., 2006; Zhang et al., 2006; O’Quigley
et al., 2001; Houede et al., 2010; Ivanova, 2003; Nebiyou Bekele and Shen, 2005; Thall
et al., 2008; Yuan and Yin, 2008; Thall et al., 2013; Koopmeiners and Modiano, 2014).
Researchers are often interested in evaluating the performance of a novel treatment
in a number of patient populations, which may or may not have different background
standards-of-care. Typically, investigators complete separate dose-escalation studies to
establish the MTD in each population, which is an expensive and time-consuming pro-
cess. Furthermore, while it is important to understand the behavior of the new drug
in each population, it is also likely that the performance will be similar across popu-
lations, in which case researchers could gain efficiency and more precisely identify the
optimal dose by sharing information across populations. This motivates a hierarchical
modeling (HM) approach where parallel designs are run in each patient population but
information is shared across populations to gain efficiency.
In Chapter 3, we investigated HM in the context of Phase I dose-escalation studies.
We proposed three hierarchical extensions of commonly used dose-toxicity models in
Phase I clinical trials and proposed dose-finding guidelines that protect patient safety,
while allowing the design to fully realize the potential of HM. Our simulation results
indicate incorporating HM into Phase I dose-finding trials results in an increase in
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the probability of correctly identifying the MTD and the average number of patients
treated at the MTD, with little impact on the rate of DLTs. In this chapter, we pro-
pose a Bayesian adaptive Phase I-II dose-escalation design that uses HM to estimate
population-specific optimal doses, while sharing both dose-toxicity and dose-efficacy
information across populations. First, we discuss three hierarchical extensions to com-
monly used probability models for efficacy and toxicity in Phase I-II clinical trials and
adapt the dose-finding algorithm proposed in Chapter 3 to Phase I-II clinical trials.
Our simulation results indicate that HM results in an increased probability of correctly
identifying the optimal dose and increases the average number of patients treated at the
optimal dose, with limited impact on the percent of DLTs observed in the trial.
The remainder of this chapter proceeds as follows. In Section 4.2, we describe three
joint probability models for toxicity and efficacy that incorporate HM for sharing in-
formation across populations in Phase I-II dose-finding trials. First, we consider both
parametric and non-parametric bivariate binary outcome model, and, in addition, we
consider an under-parameterized model that combines toxicity and efficacy into a single
trinary outcome. In Section 4.3, we describe our dose-finding algorithm and present
simulation results evaluating the operating characteristics of our proposed design in
Section 4.4. Finally, we conclude with a discussion in Section 4.5.
4.2 Models
In this section, we present hierarchical extensions of three joint probability models for
efficacy and toxicity that have been proposed for use in Phase I-II dose-finding tri-
als. In each case, we define a two-level Bayesian hierarchical model where the first
level specifies the population-level parameters and the second level facilitates borrow-
ing across populations. Existing joint probability models for Phase I-II clinical trials
can be broadly classified into two groups: bivariate outcome models, where separate
dose-response models are specified for efficacy and toxicity and the correlation between
efficacy and toxicity is incorporated into the model using a copula model or some other
approach (Braun, 2002; Thall and Cook, 2004; Yin et al., 2006), and trinomial models,
where efficacy and toxicity are combined into a trinomial outcome and a dose-response
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relationship is specified for the trinomial outcome (Thall and Russell, 1998; Zhang et al.,
2006). We begin by discussing hierarchical extensions of two bivariate binary outcome
models and then discuss a hierarchical extension of the trinomial model proposed by
Zhang et al. (2006).
4.2.1 Bivariate Binary Outcomes
We use the following notation throughout Section 4.2.1. First, let Tikj be a binary
indicator for the presence or absence of DLT in subject i treated at dose j in population
k, which takes the value 1 with probability piT,kj , and let Eikj be a binary indicator for
the probability of tumor response in subject i treated at dose j in population k, which
takes the value 1 with probability piE,kj . We will consider two approaches for specifying
a bivariate outcome model. First, we consider a parametric approach, where parametric
dose-response models are specified for efficacy and toxicity. Next, we consider a non-
parametric model that imposes a monotonicity constraint on the dose-toxicity model
but avoids a formal parametric model.
Parametric Model
For our parametric model, we extend a simple one-parameter power model for toxicity
and a more flexible, quadratic logistic regression model for efficacy. Our hierarchical
model for toxicity is specified as:
pr(Tikj = 1|population = k, dose = j) = piT,kj = pexp(αk)j (4.1)
αk|µT , σ2T ∼ N(µT , σ2T )
µT ∼ Normal(0, 22) and σT ∼ Uniform(0.39, 3)
for dose level j = 1, . . . , D and population k = 1, . . . ,K. The vector (p1, . . . , pD) is
referred to as the skeleton and its components are monotonically increasing and take
values between 0 and 1. For our simulation results presented in Section 4.4, we set the
power model skeleton equal to (0.05, 0.15, 0.25, 0.35, 0.45). Our hierarchical model for
efficacy is specified as:
pr(Eikj = 1|population = k, dose = j) = piE,kj = β0k + β1k(dose− 1) + β2k(dose− 1)2,
(4.2)
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βlk|µl, σ2l ∼ Normal(µl, σ2l )
µl ∼ Normal(ml, s2l ) and σl ∼ Uniform(0.39, 3),
for l = 0, 1, 2, dose level j = 1, . . . , D and population k = 1, . . . ,K. We originally fixed
the intercept equal to -3 to reduce the number of unknown parameters, as suggested
by Goodman et al. (1995). This reflects a 5% probability of tumor response at dose
level 1, but we found that this model did not provide enough flexibility when the true
optimal dose resides in the higher dose levels. The unknown m0, m1, and m2 are the
shared mean hyper-parameters for the intercept, linear and quadratic terms and are
set equal to -2, 0.1, and 0, respectively, with shared variance hyper-parameters set to
s20 = 4, s
2
1 = 9, and s
2
2 = 4. This corresponds to a conservative, monotonic prior efficacy-
skeleton of 0.12, 0.13, 0.14, 0.15, 0.17 for dose levels 1, 2, 3, 4, 5, respectively. The σ2l
are our hierarchical variance parameters that control the amount of borrowing across
populations, with smaller values indicating more borrowing. We specify a uniform prior
distribution on the standard deviation, rather than the log standard deviation, as in
Chapter 3, since this prior is well-received for other hierarchical applications and we
are interested in exploring its use further in our dose-finding setting. In Chapter 3, a
uniform prior on the standard deviation with a lower bound of 0 produced poor conver-
gence and identifiability, given the small sample sizes early in a trial. The lower bound
of our uniform prior was set to 0.39, based on our simulation results, which suggested
that a lower bound less than 0.39 results in over-borrowing and poor trial operating
characteristics.
The toxicity and efficacy outcomes in Phase I-II clinical trials are thought to be corre-
lated and previous authors proposing bivariate outcome models for Phase I-II clinical
trials have used copula models to specify the correlation (Thall and Cook, 2004; Braun,
2002). Copula models are complex models that require a large amount of data to prop-
erly model the correlation between outcomes. Previously, we illustrated that the sample
sizes found in Phase I-II clinical trials are typically inadequate to estimate the correla-
tion parameters in copula models and that the performance of Phase I-II trial designs is
not diminished if the two endpoints are assumed to be independent, even in the presence
of strong correlation (Cunanan and Koopmeiners, 2014). Other authors have reported
similar results (Yin et al., 2006). Therefore, we will proceed assuming independence
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between the toxicity and efficacy outcome for our parametric model.
Non-Parametric Model
The second model we consider is a hierarchical extension of the non-parametric model
proposed by Yin et al. (2006). They specify a dose-response relationship for toxicity
and efficacy through the following transformations. For population k = 1, . . . ,K, the
dose-response model for toxicity is specified as,
φk1 = logit(piT,k1), φkj = log
(
piT,kj
1− piT,kj −
piT,k(j−1)
1− piT,k(j−1)
)
,
for j = 2, . . . , D, and for efficacy, let
ψk1 = logit(piE,k1), ψkj = log
(
piE,kj
1− piE,kj
)
− log
(
piE,k(j−1)
1− piE,k(j−1)
)
,
for j = 2, . . . , D. The primary difference between the two parameterizations is that
the model for toxicity enforces a monotonicity constraint on the dose-response relation-
ship for toxicity, whereas the model for efficacy does not. Yin et al. (2006) originally
specified a bivariate normal prior for the efficacy and toxicity parameters to allow a
prior correlation between the model parameters but found that setting the off-diagonal
covariance elements to zero did not impact their results. We will specify independent
normal priors for φj,k and ψj,k and facilitate borrowing strength across populations by
specifying a hierarchical model on φkj and ψkj as follows:
φkj |µφ,j , σ2φ,j ∼ Normal(µφ,j , σ2φ,j) (4.3)
µφ,j ∼ Normal(0, 50) and σφ,j ∼ Uniform(0.39, 3)
and,
ψkj |µψ,j , σ2ψ,j ∼ Normal(µψ,j , σ2ψ,j) (4.4)
µψ,j ∼ Normal(0, 50) and σψ,j ∼ Uniform(0.39, 3)
for dose level j = 1, . . . , D and population k = 1, . . . ,K. Yin et al. (2006) specify a
Normal(0, 100) prior on φj and ψj . Our design, which uses HM to share information
across populations, will have a smaller sample size for each population than would typi-
cally be used in an independent Phase I-II design. To accommodate the smaller sample
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size, we reduce the prior variance to 50. Similar to the parametric binary bivariate
model, σ2ψ,j and σ
2
ψ,j are our hierarchical variance parameters, controlling the amount
of sharing across populations, and were specified using simulation studies, as described
at the end of this section.
The dose-response models specified above provide the marginal probabilities of tox-
icity and efficacy. Yin et al. (2006) induce correlation between the toxicity and ef-
ficacy outcomes using the global cross-ratio model proposed by Dale (1986). Define
pixy,kj = Pr(Tkj = x,Ekj = y|population = k,dose = j) with x ∈ {0, 1} and y ∈ {0, 1}.
Under the global cross-ratio model, the toxicity-efficacy odds ratio (OR) is defined as
follows:
θkj =
pi00,kjpi11,kj
pi01,kjpi10,kj
,
where θkj quantifies the association between the two outcomes for population k at dose
level j. Yin et al. (2006) specify a logNormal(0, 10) prior distribution for each θj and
assume all θj ’s are independent to ease computation. To reduce our parameter space,
we define θkj ∼ logNormal(0, 5), rather than define a hierarchical structure to share
information across populations when estimating the odds ratio. Recall that we will share
information across populations for estimating the probability of toxicity and efficacy
through the hierarchical models specified in Equations (4.3) and (4.4) and feel that
specifying an additional hierarchy for the odds ratio is unnecessary. Finally, we reduce
the prior variance for the odds ratio to accommodate a smaller sample size for each
population compared to an independent design for each population. After accounting
for the correlation induced by the global cross-ratio model, the joint toxicity and efficacy
outcomes for dose j and population k follow a multinomial distribution with response
probabilities (pi11,kj , pi10,kj , pi01,kj , pi00,kj) and a sample size of nkj patients, where the
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response probabilities are defined as follows (Dale, 1986):
pi11,kj =
 (akj −
√
a2kj + bkj/{2(θkj − 1)}, for θkj 6= 1
piT,kjpiE,kj , for θkj = 1
pi10,kj = piT,kj − pi11,kj
pi01,kj = piE,kj − pi11,kj
pi00,kj = 1− piT,kj − piE,kj + pi11,kj ,
with akj = 1 + (piT,kj + piE,kj)(θkj − 1) and bkj = (−4)θkj(θkj − 1)piT,kjpiE,kj .
4.2.2 Trinary Outcome
The last model we consider is a hierarchical extension of the triCRM proposed by Zhang
et al. (2006). Rather than separately modeling bivariate binary outcomes, they collapse
the four possible outcomes into a single variable with three outcomes: no efficacy or
toxicity, efficacy without toxicity and toxicity with or without efficacy. An advantage
to this approach is that the model is simple relative to the other models, since we do
not have to model separate dose-response models for the two outcomes, but a disad-
vantage is that the marginal probability of efficacy is no longer identifiable. However,
our primary interest is identifying doses with sufficient efficacy and acceptable toxicity,
mitigating the impact of this disadvantage.
Denote the probabilities of the three possible outcomes (no efficacy or toxicity, efficacy
without toxicity, toxicity with or without efficacy) as ψ0, ψ1, ψ2, respectively, which by
definition sum to 1. We can define a hierarchical extension of the continuation-ratio
model proposed by Zhang et al. (2006) as follows:
log
(
ψ1,kj
ψ0,kj
∣∣∣∣ population = k, dose = j) = α1k + α2k + γ1k(dose) (4.5)
logit(ψ2,kj |population = k, dose = j) = α1k + γ2k(dose),
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for dose levels j = 1, . . . , D and population k = 1, . . . ,K, with hierarchical priors defined
as follows:
αtk|µαt, σ2αt ∼Normal(µαt, σ2αt)
γtk|µγt, σ2γt ∼Normal(µγt, σ2γt)
µαt ∼ Normal(ut, c2t ) and σαt ∼ Uniform(0.39, 3)
µγt ∼ Normal(vt, b2t ) and σγt ∼ Uniform(0.39, 3)
for t = 1, 2 with u1 = −3, u2 = 2, v1 = 0.5, v2 = 1, and c1 = c2 = b1 = b2 = 4. The
second level mean specifications correspond to a prior toxicity skeleton, i.e., ψ2, of 0.12,
0.27, 0.50, 0.73, 0.88 for dose levels 1, 2, 3, 4, 5, respectively; and a prior skeleton for
efficacy with no toxicity, i.e., ψ1, of 0.33, 0.37, 0.31, 0.20, 0.10 for dose levels 1, 2, 3, 4,
5, respectively, which results in a prior skeleton for no response, i.e., ψ0, of 0.55, 0.37,
0.19, 0.07, 0.02 for dose levels 1, 2, 3, 4, 5, respectively. As in the binary bivariate
models, σ2αt and σ
2
γt are our hierarchical variance parameters, controlling the amount of
sharing across populations, and were specified using simulation studies, as described in
Section 4.2.3.
There is one major difference between our hierarchical model and the original model
proposed by Zhang et al. (2006). For simplicity and computational ease, Zhang et al.
(2006) define a Uniform(−10, 5) prior for the common intercept α1k, a Uniform(0, 10)
prior on the second intercept α2k, and Uniform(0, 10) priors on the slope parameters
γ1k and γ2k. These priors impart the following restrictions on the model: (i) the prob-
ability of no response, ψ0, decreases monotonically with dose, (ii) the probability of
toxicity with or without efficacy, ψ2, increases monotonically with dose, and (iii) the
probability of efficacy without toxicity, ψ1, may or may not be monotone with dose.
In contrast, our hierarchical model has no such restrictions. We originally considered
hierarchical prior specifications that maintained these restrictions but found them to
be difficult to implement computationally. Furthermore, our simulation results suggest
that our model performs well without these restrictions and, hence, we proceed with
the hierarchical model presented above.
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4.2.3 Hyperparameter Specification
The hyperparameters for the models discussed above were determined by simulation,
as follows. The second-level mean hyperparameters were determined by separately
varying each parameter in the corresponding independence model and selecting the
combination with the most robust performance, as evaluated by simulation. We specify
a uniform prior for the second-level standard deviation. The lower bound for the uniform
prior distribution was set greater than zero due to the small sample sizes found in
Phase I clinical trials, especially early in the trial, in which case the model cannot
rule out a population variance of zero, resulting in an invalid distribution for our first
level probability model. After fixing the mean hyperparameters, we selected the hyper-
parameters for the standard deviation for each model by progressively increasing the
lower bound for our uniform prior and selecting the value with the most robust operating
characteristics, as evaluated by simulation. We note simulations were similar for a
larger lower bound for the non-parametric bivariate binary model, however, we chose
the smaller value to be consistent with the other models.
4.3 Dose-Finding Algorithm
In this section, we discuss dose-finding when using hierarchical modeling to share in-
formation across populations in Phase I-II clinical trials. We expect enrollment to be
staggered and randomly distributed across populations. In Chapter 3, we discussed
three dose-finding guidelines that define when to allow dose-escalation within a popu-
lation taking into account the number of patients observed in other populations. These
guidelines are incorporated for patient safety but our simulation results suggest that
our guidelines result in improved operating characteristics based on a number of met-
rics, compared to unrestricted dose-finding. In this chapter, we consider only a single
dose-finding guideline based on our results from Chapter 3.
We identify a set of acceptable doses for each population, assuming admissibility crite-
ria and minimum performance levels as elicited from clinicians. For each population,
we determine the optimal dose from the set of acceptable doses by maximizing each
population’s posterior mean probability of efficacy without toxicity, following the work
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of Yin et al. (2006). For the parametric bivariate model, the two binary outcomes are
assumed independent and the probability of efficacy with no toxicity for each dose is
simply the product of the marginal probability of efficacy and the marginal probability
of toxicity. For the non-parametric bivariate model, the optimal dose is determined
by pi01, the multinomial probability for efficacy with no toxicity. For the two bivariate
binary outcome models described in Section 4.2.1, a dose is acceptable if the poste-
rior probability of a DLT being less than the clinician-specified target toxicity level
and the posterior probability of an efficacious response exceeding the clinician-specified
minimum threshold for efficacy both exceed pre-specified minimum thresholds, i.e.,
Pr(piTk < piT |Data,Dose) > γT and Pr(piEk > piE |Data,Dose) > γE (4.6)
where piT is the maximum acceptable probability of DLT, piE is the minimum accept-
able probability of efficacy, and γT and γE are the minimum pre-specified thresholds
for toxicity and efficacy, respectively. These are admissibility criteria for toxicity and
efficacy proposed by Thall and Cook (2004). The thresholds γT and γE are typically
chosen between 0.05 and 0.20 and can be thought of as tuning parameters to achieve
desired trial operating characteristics (Berry et al., 2010).
We cannot use the acceptability criteria described above for the trinary model because
although the marginal probability of toxicity can be estimated, the marginal probability
of efficacy is not identifiable. Instead, we use two decision functions proposed by Zhang
et al. (2006) to determine the set of acceptable doses and, among those found to be
acceptable, the optimal dose. We denote ψˆ0,kj , ψˆ1,kj , ψˆ2,kj to be the posterior mean
probabilities of no toxicity or efficacy, efficacy without toxicity, and toxicity with or
without efficacy, respectively. The first decision rule determines the set of acceptably
safe doses using:
δ1,kj = I(ψˆ2,kj < piT ) (4.7)
Given that a dose is acceptable, i.e., δ1,kj = 1, Yin et al. (2006) determine the optimal
dose from the set of acceptable doses by maximizing the toxicity-adjusted treatment
success rate,
δ2,kj = ψˆ1,kj − λψˆ2,kj , (4.8)
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where 0 ≤ λ ≤ 1 is a weight for the posterior mean probability of toxicity, ψˆ2,kj . If
we set λ = 0, the decision rule to determine the optimal dose is the dose maximizing
the posterior mean probability of efficacy with no toxicity. We can also consider using
δ1,kj for the two models presented in Section 4.2.1. However, these models are over-
specified and using δ1,kj with these models results in more trials stopping early due to
poor estimation. Finally, we also modify Zhang et al. (2006)’s decision function, δ1,kj ,
to require a minimum performance level for efficacy,
δ∗1,kj = I(ψˆ2,kj < piT )× I
(
ψˆ1,kj
ψˆ0,kj + ψˆ1,kj
> piE|T c
)
. (4.9)
That is, we require the posterior mean probability of efficacy conditional on no toxicity
to be greater than some minimum pre-specified threshold in addition to the toxicity
decision criteria found in (4.7).
In a standard Phase I-II clinical trial, the initial cohort of (typically) three patients
is treated at the lowest dose level and subsequent cohorts are treated at the current
estimate of the optimal dose based on the outcomes for all previous subjects under
the restriction that no untried dose-level may be skipped when escalating. Extending
this approach to hierarchical modeling with multiple populations is not straightforward.
One approach would be to escalate in cohorts of three patients regardless of the popu-
lation, but this would be too aggressive and potentially result in a patient being treated
at a dose-level before other patients from the same population are treated at a lower
dose-level. Alternately, escalation could occur using cohorts of three patients within a
population but this would not take full advantage of sharing information across popu-
lations using hierarchical modeling. Instead, we will use the “m/1(m+ 1)” dose finding
guideline (DFG) described in Chapter 3. The “m/1(m + 1)” DFG provides a run-in
period for each population and indicates when a population is able to escalate to an
untried dose, but the ultimate decision to escalate is based on the current estimate of
the optimal dose. Formally, the “m/1(m+1)” DFG allows escalation to dose-level j+1
for population k = 1, . . . ,K if:
• m patients in population k,
• Or m + 1 patients overall (and at least 1 patient in population k),
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have been treated at dose level j, for j = 1, . . . , D − 1. This DFG will encourage esca-
lation, when appropriate, but was shown in Chapter 3 to effectively limit the number
of DLTs and patients treated at overly toxic dose-levels.
Yin et al. (2006) propose that the trial should escalate to the next untried dose level
if there is high posterior probability that the probability of DLT for the highest tried
dose is less than the target toxicity level, i.e.,
Pr(piTk < piT |Data,Dosemax) > p, (4.10)
where p ≥ γT . With the complex models used in Phase I-II clinical trials, it can be dif-
ficult to estimate the dose-response curves when there are multiple untried dose-levels.
Criterion (4.10) encourages escalation when there are untried dose levels that appear
to be sufficiently safe. Once a population is allowed to escalate, as determined by the
“m/1(m+ 1)” DFG, we implement the above escalation rule.
In summary, our proposed Phase I-II design will proceed as follows:
1. Treat the first patient in each population at the lowest dose level.
2. When a new patient is enrolled, determine if their population is allowed to escalate
(or de-escalate) as determined by the “m/1(m + 1)” DFG and if so, update the
posterior distribution for all model parameters using all available data. Otherwise,
treat the next patient at the current dose-level.
3. If escalation is allowed, determine the set of acceptable dose-levels for the current
population using Criteria (4.6) for the bivariate models or Criteria (4.9) for the
trinomial model. The trial terminates for futility if all dose-levels are unacceptable
and Criterion (4.10) is not satisfied.
4. Otherwise, treat the next patient at the dose level that maximizes either pi01,kj ,
for the bivariate models, or δ2,kj , for the trinomial model, under the restriction
that untried dose-levels cannot be skipped when escalating. If Criterion (4.10) is
satisfied, the next patient will be treated at the lowest untried dose-level.
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5. Repeat steps 2-4 until the maximum overall sample size is reached. Within each
population, the acceptable dose that maximizes either pi01,kj or δ2,kj (depending
on the model) at study completion is considered the optimal dose.
4.4 Simulation Study
We conducted a simulation study to evaluate the operating characteristics of a Phase
I-II clinical that incorporates hierarchical modeling using the models discussed in Sec-
tion 4.2. Design performance was summarized by (i) the probability of correctly iden-
tifying each population’s biologically optimal dose (BOD), (ii) the percent of patients
experiencing a DLT, and (iii) the average number of patients treated at each popu-
lation’s BOD. Simulations were completed assuming the following design parameters.
The target toxicity level was set to piT = 0.3 and the minimum efficacy level was set to
piE = 0.3. Gatekeepers defining acceptable doses were set to γT = 0.25, γE = 0.1 for
Criteria (4.6) and piE|T c = 0.1 for Criteria (4.9). We set p = 0.5 for Criterion (4.10),
which encourages escalation to untried doses if all tried doses have been shown to be
safe. We assume K = 5 populations with uniform enrollment across populations and
D = 5 dose levels for investigation. We assume a maximum sample size of 100 total
patients, with a minimum of 3 patients per population. This corresponds to an average
of 20 patients in each population. Gibbs and slice sampling were completed in JAGS via
R using rjags (Plummer, 2011). Posterior inference was completed using 5,000 MCMC
samples following a period of 1,000 iterations for burn-in. 1000 simulated trials were
completed for each scenario.
For comparison, we also evaluate the operating characteristics assuming independent
trials were completed for each population. Simulations were completed with models
analogous to the three models discussed in Section 4.2. In each case, we fit the model
specified in Section 4.2 without the second level of the hierarchy. A maximum of 20
subjects per population was used for the independent designs.
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4.4.1 Scenarios
Data were simulated from one of four scenarios. Each scenario included five populations.
The dose-toxicity and dose-efficacy curves for each population were generated from one
of the thirteen cases discussed by Yin et al. (2006). The dose-toxicity and dose-efficacy
curves for each case are presented in Figure 4.1. We define the BOD to be the dose
that maximizes pi01 (black dot) or δ2(λ = 0), with δ
∗
1 defining acceptable doses (square),
depending on the model. Other decision rules for selecting the optimal dose include
minimizing the toxicity-efficacy odds ratio (open circle) and maximizing δ2(λ = 0) with
Zhang et al. (2006)’s original decision function δ1 to define acceptable doses (x). In
Scenario 1, the same combination of dose-toxicity and dose-efficacy curves were used
for all five populations (Case 1), where the lowest dose is the optimal dose. In Scenario
2, population one uses the curves from Case 3, where toxicity and efficacy increase at
the same rate (OR = 1) and there is no optimal dose, and the other four populations
use the curves from Case 13, where dose four is optimal. In Scenario 3, the populations
are more heterogeneous and the optimal dose varies substantially across populations.
Specifically, Scenario 3 is comprised of Cases 3, 9, 1, 8 and 11, which have no optimal
dose, no optimal dose, optimal dose equal to dose one, optimal dose equal to dose three,
and optimal dose equal to dose three, respectively. Finally, in Scenario 4, the optimal
dose differs by population but is clustered around the intermediate dose-levels. Scenario
4 is comprised of Cases 6, 7, 8, 10 and 13, which have optimal doses of dose level four,
three, three, two and four, respectively.
4.4.2 Results
Figure 4.2 shows results for Scenarios 1 and 2. Figure 4.2 presents the probability of
correctly identifying the optimal dose (top plots), the percent of patients experiencing
a DLT (middle plots), and the average number of patients treated at the optimal dose
(bottom plots). In Scenario 1, all populations have the same dose-toxicity and dose-
efficacy curves, resulting in the same optimal dose for all populations (dose level 1).
We see that hierarchical modeling results in an increase in the probability of correctly
identifying the optimal dose with the parametric bivariate model (displayed as “PLR
HM”) showing the best performance, while the non-parametric bivariate model showed
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Figure 4.1: Thirteen combinations of dose-toxicity and dose-efficacy curves from Yin
et al. (2006). The optimal dose based on different decision criteria are displayed above
the pre-specified dose levels on the x-axis, and denoted as: (open circle) toxicity-efficacy
odds ratio, (black dot) joint posterior probability of no toxicity with efficacy, (x) Zhang
et al. (2006) decision rule with λ = 0, and (square) alteration: posterior probability
of efficacy conditional on no toxicity, Zhang et al. (2006) decision rule with λ = 0.
The dose-toxicity and dose-efficacy curves are represented with red and blue lines, re-
spectively. The grey line displays the upper toxicity and lower efficacy limits for our
posterior probabilities. Scenario 1: All five populations assume dose-response curves
from Case 1. Scenario 2: Cases 3, 13, 13, 13, and 13 for populations 1, 2, 3, 4, and 5,
respectively. Scenario 3: Cases 3, 9, 1, 8, 11. Scenario 4: Cases 6, 7, 8, 10, 13.
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relatively little improvement (displayed as “OR HM”). A possible concern related to
our design is that our more aggressive dose-finding algorithms might increase DLTs,
but our results suggest that the rate of DLTs is similar across models both with and
without HM. In addition to increasing the probability of correctly identifying the opti-
mal dose, hierarchical modeling also increased the average number of patients treated
at the optimal dose, although in this case, the hierarchical trinomial model (displayed
as “Tri HM”) displayed better performance than the PLR HM. These results highlight
the benefits of hierarchical modeling: when the populations are homogenous and it is
appropriate to share across populations, HM increases the probability of correctly iden-
tifying the optimal dose and the number of patients treated at the optimal dose with
limited impact on the number of DLTs observed in the trial.
In Scenario 2, the last four populations are homogeneous (Case 13, where dose 4 is
the optimal dose), while the first population has no dose level with an acceptable ef-
ficacy/toxicity trade-off (Case 3). This is a challenging scenario because the last four
populations will encourage borrowing across populations but this could result in incor-
rectly borrowing strength from the first population, where no dose is acceptable. For
the last four populations, HM greatly out-performs the independent models in correctly
identifying the optimal dose and in treating more patients on average at the optimal
dose, with limited impact on the probability of DLTs. This behavior is to be expected
because the larger pooled sample size results in a more precise estimate of the BOD and
allows individual populations to escalate more quickly than the independent designs.
Comparing across hierarchical models, we see that the OR HM model has the best per-
formance and largest improvement over its corresponding independence design, while
the PLR HM and Tri HM have similar performance. For the first population, where no
dose has an acceptable efficacy/toxicity trade-off, we see that HM decreases the proba-
bility of drawing the correct conclusion, with the two bivariate models exhibiting worse
performance than the Tri HM model. This is to be expected due to the more stringent
acceptability criterion used by the trinomial model. Finally, we note that while the HM
designs decreased the probability of correctly concluding that no dose level is accept-
able, HM had little impact on the number of DLTs observed with little increase over
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Figure 4.2: (Left column) Trial operating characteristics from 1000 simulated trials
for Scenario 1 by population: (top) selection probability for the population-specific bio-
logically optimal dose (BOD); (middle) percentage of dose-limited toxicities; (bottom)
average number of patients treated at the population specific BOD, for the three hier-
archical and independence designs. The first two bars (black and dark grey; labelled
“PLR HM” and “PLR Ind.”, respectively) present results using the parametric bivariate
binary models. The next two bars (darker grey and grey; labelled “OR HM” and “OR
Ind.”, respectively) present results using the non-parametric bivariate binary models.
The last two bars (light grey and white; labelled “Tri HM” and “Tri Ind.”, respectively)
present results for the parametric trinary model. For each scenario, the population’s
case-index used for data generation is presented on the x-axis. (Right column) Simula-
tion results for Scenario 2.
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the independence designs.
Results for Scenarios 3 and 4 can be found in Figure 4.3. Scenario 3 is another dif-
ficult case, where all doses have an unacceptable efficacy/toxicity trade-off in the first
two populations (Cases 3 and 9, respectively), dose-level 1 is the optimal dose in the
third population (Case 1) and dose-level 3 is the optimal dose for the last two popu-
lations (Cases 8 and 11, respectively). The results for Scenario 3 are consistent with
our previous results. The three hierarchical models are more likely to correctly identify
the optimal dose and treat more patients, on average, at the optimal dose when an
optimal dose exists (last three populations) but the HM approaches are also more likely
to incorrectly conclude that an optimal dose exists when no dose level has an acceptable
efficacy/toxicity trade-off, although we again note that the impact on the total number
of DLTs is minimal with the PLR HM having the highest DLT rate and Tri HM hav-
ing the lowest DLT rate from among the three HM designs. Finally, comparing across
hierarchical models, we see that the Tri HM design has the best performance of the
three hierarchical models, treating more patients at the optimal dose and fewer patients
above the optimal dose than the other two models.
In Scenario 4, there is modest heterogeneity in the optimal dose with the optimal dose
varying from dose level 2 to dose level 4. We believe that this scenario best represents
what we might expect to see in practice, for two reasons. First, investigators are ad-
vised to select their dose range such that the optimal dose is likely to be an intermediate
dose based on pre-clinical data. Second, this scenario represents the case where the op-
timal dose is similar across populations but there is some variability due to different
background treatments for each population. In this case, we see that the hierarchical
extensions are more likely to correctly identify the optimal dose and treat more patients,
on average, at the optimal dose in all populations. Among the hierarchical designs, the
trinomial model performs the best across all populations. Again, HM has only a mod-
est impact on the DLT rate compared to the independence designs, with the Tri HM
again having the lowest DLT rate from among the three hierarchical designs and the
PLR HM design having the highest. A possible solution to decreasing the DLT rate for
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Figure 4.3: (Left column) Trial operating characteristics from 1000 simulated trials
for Scenario 3 by population: (top) selection probability for the population-specific bio-
logically optimal dose (BOD); (middle) percentage of dose-limited toxicities; (bottom)
average number of patients treated at the population specific BOD, for the three hier-
archical and independence designs. The first two bars (black and dark grey; labelled
“PLR HM” and “PLR Ind.”, respectively) present results using the parametric bivariate
binary models. The next two bars (darker grey and grey; labelled “OR HM” and “OR
Ind.”, respectively) present results using the non-parametric bivariate binary models.
The last two bars (light grey and white; labelled “Tri HM” and “Tri Ind.”, respectively)
present results for the parametric trinary model. For each scenario, the population’s
case-index used for data generation is presented on the x-axis. (Right column) Simula-
tion results for Scenario 4.
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the PLR HM design is to increase γT when using the parametric bivariate model but
the impact of increasing γT on the other operating characteristics is a potential concern.
In summary, our simulation results highlight the benefits of HM in Phase I-II dose-
finding trials. Incorporating HM resulted in an increased probability of correctly iden-
tifying the optimal dose and treating more patients at the optimal dose than the in-
dependent designs, with only a modest increase in the probability of DLT. Comparing
the three hierarchical models discussed in Section 4.2, the trinomial hierarchical model
resulted in the best trade-off between correctly sharing information across populations
when the populations were homogeneous and over-sharing when the populations were
heterogeneous. In addition, the trinomial model treated more patients at the optimal
dose than the other two models, in most cases. In contrast, our simulation results sug-
gest that implementing HM in the bivariate binary models and the parametric model, in
particular, is not ideal. Both models were less likely to correctly declare all doses futile
or unsafe and resulted in more DLTs when populations were heterogeneous compared
to the trinomial model. Furthermore, they did not provide substantially more benefits
than the trinomial model when populations were homogeneous.
4.5 Discussion
In this chapter we discussed HM for sharing information across populations in Phase
I-II clinical trials. First, we presented two bivariate models, one parametric and one
non-parametric, for modeling the dose-response relationship for efficacy and toxicity.
Dose-finding using these models implemented the acceptability criteria defined by Thall
and Cook (2004) to identify acceptable dose-levels with the optimal dose defined as the
one maximizing the probability of efficacy with no toxicity (Yin et al., 2006). Next,
we presented a hierarchical extension of the trinary outcome model proposed by Zhang
et al. (2006), which combined the two binary outcomes into a single, trinary outcome.
Reducing the two binary outcomes to a single trinary outcome precluded the direct
application of acceptability criteria defined by Thall and Cook (2004) and instead we
adapted the decision functions proposed by Zhang et al. (2006) for identifying the op-
timal dose with the trinary model.
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Our simulation results suggest that the two hierarchical bivariate outcome models out-
performed the trinary model when the populations are homogeneous and, in particular,
the non-parametric bivariate model performed very well when the populations are ho-
mogeneous and the optimal dose is one of the higher dose-levels. On the other hand,
the two bivariate outcome models did not perform as well when the populations were
heterogeneous, and performed particularly poorly when no dose was acceptable. In con-
trast the trinary model emerged as simpler and, as a result, exhibited more consistent
performance than the other two models.
The methods presented in Section 4.2.1 implement the design parameters from Yin
et al. (2006). Our results suggest that additional tuning is required for the paramet-
ric bivariate model, especially for the toxicity acceptability criterion, γT . As with any
Bayesian analysis, the results presented in Section 4.4.2 depend on the prior distri-
bution and prior dose-response skeleton. While the trinomial model’s prior skeleton
corresponds to a higher optimal dose level a priori, this method exhibits the best per-
formance with respect to preventing escalation to overly toxic dose-levels. In the future,
we would like to investigate more prior distributions for the pooling variance parameter
of the hierarchical trinomial model.
While our primary interest was in the performance of the three hierarchical models,
the comparison of the three independent designs is also of interest because, to the best
of our knowledge, these three models have never been compared using the same sce-
narios. While the dose-finding algorithms are different, it is interesting to note how
the simpler yet conservative method performs against the more complex and flexible
methods. Comparing both dose-finding designs under the same scenarios motivated
the alteration to Zhang et al. (2006)’s decision function defining acceptable doses. We
incorporate an additional criterion for the probability of efficacy conditional on no tox-
icity. It would be interesting to further investigate altering the minimum response rate
for efficacy conditional on no toxicity and the acceptability threshold, i.e., a smaller
quantile of the posterior for the probability of efficacy conditional on no toxicity.
Chapter 5
Conclusion
5.1 Summary of Major Findings
In this thesis, we developed Bayesian methods for adaptive Phase I and Phase I-II clin-
ical trials. First, in Chapter 2 we considered a Phase I-II clinical trial of therapeutic
cancer vaccines. We proposed a two-stage, randomized design for identifying the optimal
vaccination schedule from a set of multiple candidate schedules. Stage one determines
which schedules, if any, satisfy a minimum clinical performance level using the DLT and
immune response rates. Schedules that achieve the minimum level of clinical perfor-
mance in stage one were compared by the expected magnitudes of immune response to
determine the optimal schedule. If an optimal schedule cannot be determined after stage
one, Bayesian predictive probabilities were used to determine the number of subjects
needed to achieve a conclusive result in stage two. Our simulation results illustrated
that incorporating the additional endpoint for the magnitude of immune response im-
proves our ability to identify the optimal schedule, and our two-stage approach using
Bayesian predictive probabilities dramatically increased the probability of achieving a
conclusive result.
In Chapters 3 and 4, we proposed Bayesian adaptive Phase I and Phase I-II trial designs
that use hierarchical modeling to share information across potentially heterogeneous
populations. We first considered Phase I trial designs and discussed hierarchical exten-
sions of three dose-toxicity models that are commonly used in Phase I clinical trials. In
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addition, we proposed three novel dose-finding guidelines that facilitate dose-escalation
in the presence of hierarchical modeling while protecting safety. Our simulation results
suggested that hierarchical modeling often achieves a more precise estimate of each pop-
ulation’s MTD and more patients treated at each population’s MTD, while maintaining
patient safety when implemented with the proposed dose-finding guidelines. The ex-
tension of the under-parameterized power model provided the best trade-off between
borrowing strength when populations are homogeneous and robustness when popula-
tions are more heterogeneous. Next, we proposed hierarchical modeling in the context
of Phase I-II clinical trials using one of the previously proposed dose-finding guidelines.
The simple model that combines efficacy and toxicity into a single endpoint appears
to performed best when using hierarchical modeling. These results further support the
use of under-parameterized hierarchical models in early phase oncology trials. The pro-
posed dose-finding guidelines did not increase the rate of DLTs when applied to Phase I
clinical trials, although our results suggest that hierarchical models are more aggressive
than the independent models when applied in Phase I-II clinical trials. Compared to the
independence design, hierarchical Phase I-II designs display a dramatic increase in the
number of patients treated at each population’s optimal dose but at the cost of treating
slightly more above each population’s optimal dose. Whether this behavior is due to the
extra complexity as a result of considering both efficacy and toxicity or over-sharing as
a result of hierarchical modeling should be investigated further. Regardless, our results
are promising and support the use of hierarchical modeling to share information across
populations in early phase dose-finding trials.
5.2 Future Work and Considerations
We used hierarchical modeling to borrow strength across similar sources of information
in Phase I and Phase I-II clinical trials. This is especially important given the lim-
ited sample sizes in early phase clinical trials. Our simulation results illustrate that
hierarchical modeling can dramatically improve estimation and increase the number of
patients receiving an active dose, with little impact on patient safety. Combining this
approach with the randomized, two-stage design proposed in Chapter 2 when more than
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two vaccination schedules are being evaluated is a subject worthy of further investiga-
tion.
Hyperparameters for our prior distributions were set by using simulation to compare
trial operating characteristics under various prior specifications and identifying the set
of hyper-parameters that provided the most robust performance. This is a common
approach when implementing Bayesian adaptive trials designs; Lee and Cheung (2011)
and Zhang et al. (2013) propose more formal approaches to specifying hyperparameters
in early phase Bayesian adaptive clinical trials. A potential future extension of our work
would be to adapt their approach to the designs proposed in this dissertation, which
could potentially improve robustness and precision. Finally, evaluating our priors in
terms of the prior effective sample size is a topic of particular interest. Following the
work of Morita et al. (2012), we can approximate the number of patients required to
achieve our prior precision under our proposed dose-finding algorithm. Prior effective
sample size is an intuitive approach for quantifying the informativeness of a prior dis-
tribution and translating our prior specification to a metric more easily quantifiable to
clinicians. This may help encourage the use of our proposed adaptive designs.
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